List of Biotech, Pharmaceutical & Life Sciences companies in Maryland - 235

20/20 GeneSystems (‘20/20’) was founded in May of 2000 to develop and promote an innovative proteomics product line that provides drug companies, biodefense specialists and life scientists with new tools for protein analysis. Our headquarters are in the heart of the biotechnology corridor in Rockville, Maryland in close proximity to the National Institutes of Health with which we have extensive collaborations. 20/20 GeneSystems develops and commercializes innovative, proprietary diagnostics tests that aid in the fight against cancer. These tests generally fall into two categories: Personalized Medicine: Our patented platform technology for measuring biomarkers in tumors is highly unique in that it combines the visual advantages of classical pathology with the multiplex capabilities needed as a result of genomics and proteomics. This technology is now being used to develop tests to predict responses to several new targeted therapies for kidney and lung cancer. Early detection of lung cancer: 20/20 is developing a blood test for the early detection of lung cancer. This product will be used for screening smokers and former smokers to pre-select or enrich the patient population to receive annual CT scanning long before the disease becomes symptomatic. Biological Detection: 20/20 is on the leading edge of developing technologies to help in the detection of biological toxins.

3CPM Corporation is a Medical Technology company that offers a non-invasive 45-minute test using AI-derived patented technology to accurately characterize gastrointestinal motility disorders such as gastroparesis and functional dyspepsia.

AAVnerGene Inc is an innovative company specialized in AAV technologies. It is founded by a group of AAV gene therapy enthusiasts who dream to serve the community, promote and lead the future of gene therapy. Our passion is to solve the bottleneck problems in AAV gene therapy and find more and better cures for all the patients. We believe that hard core technologies are the key to achieve it. With 20 years of frontline gene therapy experience, our team develops novel AAV vectors, methods and strategies that can efficiently produce, deliver and express high quality vectors into specific cells. Our goal is to increase AAV gene therapy efficacy and decrease the cost, making it accessible and affordable to patients. Our highly complex AAV capsid libraries allow us to efficiently select the best AAV capsid for each cell type in a high-throughput manner.

Our mission is to make you stronger. The company was founded by a family directly impacted by three muscle wasting diseases: Duchenne muscular dystrophy, cancer cachexia and COPD. Our fight is personal and our commitment to developing better and more effective therapies is undaunted. AVGN7 prevents muscle wasting in different animal models and can restore muscle mass and strength even after wasting has already occurred. It works when injected directly into muscle or when administered systemically to all muscles. It was also designed to avoid the potentially serious side-effects of other "myostatin attenuating" therapies. AVGN7 for the durable maintenance of muscle mass and function.

AbelZeta is a global clinical-stage biopharmaceutical company with centers of excellence in Rockville, Maryland and Shanghai, China. AbelZeta is focusing on developing innovative and proprietary cell-based therapeutic products and is committed to ushering in bespoke treatments that harness the body's own immune system to fight against hematological malignancies and solid tumors, as well as inflammatory and immunological diseases. AbelZeta advances research and development in its own GMP facilities at its centers of excellence for early-stage clinical studies, with a pipeline comprised of CAR-T and TIL therapies.

With a 60+ year history as a service provider to the life sciences industry, Advanced BioScience Laboratories (ABL) provides a strong core of product development expertise, GMP manufacturing, and analytical testing capabilities. Founded in 1961 as a biomedical research contractor for the federal government, ABL has made major contributions to the development and evaluation of a wide range of life-saving diagnostics, vaccines, and therapeutics designed to combat the world's most challenging diseases. We partner with our clients to support advancement of their candidate vaccines and therapeutics through preclinical and clinical development. With facilities located in the United States, ABL aims to be a seamless extension of our clients' team – helping them advance today's ideas into tomorrow's medicines. ABL's CDMO service division specializes in the development and manufacturing of GMP cell banks and viral vectors from the bench to Phase I/II clinical trials. We aim to contributes to the success of our clients' ground-breaking innovations, including gene therapies, immunotherapies, viral vaccines, oncolytic viruses, and more. ABL's CDMO services include bulk drug substance production, fill/finish of drug products, process development, assay development and release testing.

Acidophil is an innovation company that uses technical and business information together with bio-chemical capabilities to create, manage and co-finance new products and biotechnology businesses in human health, agriculture, and animal health. With operations in both the United States (Lutherville, MD) and United Kingdom (Cambridge), Acidophil takes a global approach to innovation, management and investment that reflects the international perspective of its team and founders. Acidophil exploits a virtual business development model to enable capital efficient innovation in collaboration with scientists, entrepreneurs, corporations and investors who are interested in addressing global market needs.

Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies addressing multi-drug resistant infections. Prior antimicrobial therapeutic approaches have been “fixed,” while pathogens continue to evolve resistance to each of those therapeutics, causing those drug products to become rapidly less effective in commercial use as antimicrobial resistance (AMR) increases over time. APT’s PhageBank™ approach leverages an ever-expanding library of bacteriophage (phage) that collectively provide evergreen broad spectrum and polymicrobial coverage. PhageBank™ phages are matched through a proprietary phage susceptibility assay that APT has teamed with Mayo Clinic Laboratories to commercialize on a global scale. APT’s technology was originally developed by the biodefense program of U.S. Department of Defense. APT acquired the world-wide exclusive commercial rights in 2017. Under FDA emergency Investigational New Drug allowance, APT has provided investigational PhageBank™ therapy to treat more than 40 critically ill patients in which standard-of-care antibiotics had failed.

At Addimmune, our mission is to deliver the world’s first functional cure for HIV. Using viral vector delivery, we are seeking to give the immune system the tools it needs to resist and ultimately clear the virus.

We are committed to the growth and development of companies and organizations using advanced therapeutic technologies to revolutionize medicine through specialized, bespoke advisory services. At Adjuvant Partners, we leverage our expertise, professional network, and pan-industry perspectives to provide unique, tailored solutions to our clients to best suit their needs. We believe in active participation with stakeholders throughout the industry, and in concert with our clientele work to foster continued growth, expansion, and implementation of advanced therapies across the healthcare spectrum.

With a 60+ year history as a service provider to the life sciences industry, Advanced BioScience Laboratories (ABL) provides a strong core of product development expertise, GMP manufacturing, and analytical testing capabilities. Founded in 1961 as a biomedical research contractor for the federal government, ABL has made major contributions to the development and evaluation of a wide range of life-saving diagnostics, vaccines, and therapeutics designed to combat the world’s most challenging diseases. We partner with our clients to support advancement of their candidate vaccines and therapeutics through preclinical and clinical development. With facilities located in the United States, ABL aims to be a seamless extension of our clients’ team – helping them advance today’s ideas into tomorrow’s medicines. ABL's CDMO service division specializes in the development and manufacturing of GMP cell banks and viral vectors from the bench to Phase I/II clinical trials. We aim to contributes to the success of our clients' ground-breaking innovations, including gene therapies, immunotherapies, viral vaccines, oncolytic viruses, and more. ABL's CDMO services include bulk drug substance production, fill/finish of drug products, process development, assay development and release testing.

AgeneBio, Inc., is an emerging pharmaceutical company dedicated to developing innovative therapeutics that prevent neurodegeneration and preserve and restore cognitive function for unserved patients battling amnestic mild cognitive impairment (aMCI), the symptomatic pre-dementia stage of Alzheimer’s disease, and other neurological and psychiatric diseases. AgeneBio’s novel pipeline of therapies is based on decades of research at Johns Hopkins University and leading research centers worldwide showing that overactivity in the hippocampus contributes to cognitive impairment and drives neurodegeneration if not controlled. This overactivity is a characteristic feature of aMCI. If approved, AgeneBio’s Phase 3-ready lead candidate, AGB101, will be the first and only therapeutic targeting hippocampal overactivity and potentially the first therapeutic to slow progression to, and delay the onset of, Alzheimer’s dementia. AgeneBio also has a novel GABA-A alpha5 small molecule program in late discovery stage with therapeutic potential for a spectrum of untreated conditions including aMCI, autism and schizophrenia. Learn more at www.agenebio.com and follow us on Twitter @AgeneBio.

Akonni Biosystems is a molecular diagnostics company that develops, and manufactures at scale, sophisticated yet low cost genetic testing devices for complex infectious diseases like multi-drug-resistant tuberculosis (MDR-TB). Our approach is based on a revolutionary gel-drop microarray platform, along with associated instrumentation for high yield sample preparation and multiplex array imaging/analysis.

Akrivita (formerly SeeTrue), a woman-owned company, specializing in microcapillary needles for precision microinjection. At AkriVita, we've developed the MultiPort Microcapillary Needle using advanced 3D printing and unique resin, ensuring precise and consistent needles. This innovative design eliminates recalibrations, reduces downtime and costs, and minimizes clogging. Our high-contrast needles offer consistent flow, improving the success rates of microinjection procedures. AkriVita provides biomedical scientists and healthcare practitioners with reliable tools that enhance outcomes, save time, and cut costs, enabling them to focus on advancing human health through discovery and innovation.

Aloe Therapeutics is a biotech start-up aimed at delivering cancer cures. We have designed a therapy, termed Allo-Immunotherapy (AIM), to trigger an influx of activated immune cells to traffic to the tumor microenvironment - turning "cold" tumors "hot" and "hot" tumors "hotter." INFLAME WITH AIM.

Alphyn Biologics is a clinical-stage dermatology company developing first-in-class multi-target therapeutics for severe and prevalent skin diseases based on its AB-101 platform. Its lead product candidate, AB-101a, is a topical treatment for atopic dermatitis (AD), the most common form of eczema, and has completed a Phase 2a clinical trial. AB-101a has demonstrated a strong safety profile and is in development to uniquely target AD's bacterial and immune system components, making it ideal for treating infected and non-infected AD. Alphyn's AB-101 platform has multiple bioactive compounds and, therefore, multiple mechanisms of action to support a robust pipeline of dermatologic therapeutics with potential safety, efficacy, and regulatory marketing authorization advantages. Alphyn is based in Annapolis, Maryland, and Cincinnati, Ohio, and has a wholly-owned subsidiary in Australia. We became operational in 2020 and have raised approximately $6.7 million.

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating treatment for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). P

Ambay Immune Sensors and Controls (AISC) is working to bring aboutá A revolution in early detection of diseasesá Speeding up the discovery process by developing new research kits and providing technical and professional services

American Gene Technologies® International Inc. (AGT™) is a private biotechnology company pursuing cures and treatments for infectious diseases, cancers, and monogenic disorders. AGT™'s emerging gene and cell therapeutics programs are designed to: ✅ Create immunotherapy for HIV disease with gene-modified T cells ✅ Activate innate T cell immunity capable of killing all tumor cells with its vector used in immuno-oncology ✅ Treat PKU by bringing a functional gene into cells that express a dysfunctional gene due to mutation ✅ Advance clinically to provide human proof of concept For over a decade, AGT™ has developed, tested, and banked thousands of lentiviral vectors that can be adapted to the specific needs of new target diseases. AGT™ has developed gene therapy for diseases using this rapid gene delivery platform. GENE THERAPIES AGT™’s platform allows it to pursue clinical “cures” for complex diseases. The company has developed patent-protected gene therapeutics that are breakthroughs in medicine. *** See our extensive award winning patents on our website *** HIV/AIDS Immunotherapy for HIV disease with gene-modified T cells IMMUNO-ONCOLOGY Activates innate T cell immunity capable of killing all tumor cells with its vector used in immuno-oncology PHENYLKETONURIA (PKU) Treats PKU by bringing a functional gene into cells that express a dysfunctional gene due to mutation AGT™'s Core Objectives ✔️ Leverage our lentivirus platform to create highly-effective targeted genetic medicines ✔️ Create solutions for patients across a spectrum of infectious diseases, cancers and inherited disorders ✔️ Collaborate with leading medical researchers from around the globe To learn more and get in touch with American Gene Technologies® Inc., contact us today at https://www.americangene.com/contact-us/

The American Society of Human Genetics (ASHG), founded in 1948, is the primary professional membership organization for human genetics specialists worldwide. The Society’s nearly 8,000 members include researchers, academicians, clinicians, laboratory practice professionals, genetic counselors, nurses and others who have a special interest in the field of human genetics. Our members work in a wide range of settings, including universities, hospitals, institutes, and medical and research laboratories. Our mission is to advance human genetics in science, health, and society through excellence in research, education, and advocacy. ASHG serves research scientists, health professionals, and the public by providing forums to: -- Share research results at annual meetings and in The American Journal of Human Genetics -- Advance genetic research by advocating for research support -- Enhance genetics education by preparing future professionals and informing the public -- Promote genetic services and support responsible social and scientific policies Connect with ASHG members and the broader human genetics community in our LinkedIn Group: https://www.linkedin.com/groups/142742

Amethyst provides cGMP compliant, custom, creative, and cost effective services (4Cs) for FDA regulated activities to increase its customers' profitability, ensure compliance, and promote patient safety.

Amivas (US), LLC is an Australian, Canadian, and US joint venture focused on the development, manufacturing, and commercialization of therapeutics for the treatment of infectious diseases. Amivas (US), LLC was formed in response to the urgent need for a US -based firm to assume responsibility for the manufacture and distribution of Artesunate for Injection, for severe malaria after quinidine gluconate was discontinued by the manufacturer. With FDA approval of its first commercial product, Amivas (US), LLC is proud to join the global effort to fight and eradicate malaria.

Amplexd is a patient-scientist led company, comprising pharmaceutical industry veterans and senior product developers blending the best of cutting-edge technology and patient-centric design to develop accessible, non-invasive treatments for HPV-induced cervical dysplasia.

Amplo Biotechnology is a private Gene Therapy company focusing on therapy for diseases of the neuromuscular junction.

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company’s lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.

Arraystar is dedicated to empower research on regulatory non-coding RNAs (ncRNAs) and the epitranscriptomics, which have become the most fascinating and forefront areas of biomedical science research. Our innovative products, in-depth expertise, and strong bioinformatics in these areas have supported over one thousand high impact publications since our 2009 inception. Over the years, our client base has expanded to thousands of eminent research institutions all around the world. Go Beyond RNA With the discoveries of novel gene regulatory activities, non-coding RNA classes represent the fundamental biology going beyond coding mRNAs and encoded proteins as the focal point of the central dogma. The pursuit to uncover pivotal roles of ncRNAs in gene regulation, programming, and orchestration has attracted intense scientific interest with alluring opportunities of finding new disease regulators, biomarkers, and therapeutic targets. While the industry of gene expression analysis has long been predominantly covering only mRNAs, Arraystar is taking the lead in supporting scientific endeavor into the once hidden yet exciting world of non-coding RNAs: lncRNAs, circular RNAs, microRNAs, tRNAs, tRFs, tiRNAs, snoRNAs and more. As a newly unveiled layer of gene regulation, epitranscriptomic modifications of coding mRNAs and non-coding RNAs determine the molecular fates and profoundly impact cellular processes, such as RNA activities, splicing, export, stability and translation in disease and health. With rapid advances in the field and new methodology development, epitranscriptomics has come of age. Arraystar is in the best position to help your research into this omics dimension of not only mRNA, but also long and small ncRNA epitranscriptomics.

AscentGene is a biotechnology company that provides high-quality cell lines and protein services to the life sciences community.

AsclepiX Therapeutics is focused on transforming the treatment of ocular diseases through the rapid clinical development of groundbreaking therapies aimed at empowering patients and their families around the world with the freedom to live their best lives. Using pioneering computational biology methods, we have identified multiple families of peptides that are potent regulators of vascular homeostasis. Our clinical candidates are derived from these peptides and work through naturally existing, highly evolved, and self-regulating mechanisms of homeostasis that maintain our health and well-being.

Autonomous Therapeutics is a synthetic immunology company developing artificial immune systems that are personalized and variant-proof. Encrypted RNA™ is a new class of RNA that enables variant-proof immunity against infectious diseases and cancers.

Avalo Therapeutics Inc. (Name changed from Cerecor Inc.) is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human brain. We are a Delaware corporation, organized in April 2011 in partnership with various laboratories and research institutes at Johns Hopkins Medical Institute ("JHMI"​). Cerecor is focused on translational medicine – the accelerated transfer of technology from the academic laboratory to early human trials, with the goal of rapid commercialization. We acquire rights to early stage therapeutic technologies ("assets"​) from universities, finance and manage the development of these assets into drug candidates (to first major milestone or value inflection point) and then either commercialize or outlicense the asset.

What We Do We focus on rapid, easy-to-use, lateral-flow immunoassays. We develop the crucial reagents, such as gold sols, gold conjugates, gold ribbon, etc. that are the backbone of any high-performance lateral-flow device. Superior reagents, coupled with our development and manufacturing expertise, yield superior assays. BioAssay Works, LLC powers the development of the finest rapid immunoassays. Utilizing our high sensitivity concentrated gold sols, high-performance gold conjugates, and our patented lateral-flow test platform, BAW develops and manufactures rugged lateral-flow tests that rival the sensitivity of ELISA. These tests can be read visually for quick positive/negative results or with simple instruments for more quantitative results. BAW offers a growing line of products that enable researchers and assay developers to create their own rapid assays. In addition, we are the assay-development partner-of-choice for both early-stage and established companies. We have the capability to manufacture and package your rapid assay, regardless of the volume required. BAW has developed a wide variety of assays for our clients, including assays for: Disease biomarkers In-process testing of pharmaceutical products Food allergens and agricultural targets Pathogens and toxins Veterinary applications Characterization and quantification of monoclonal antibodies

BioFactura develops and commercializes biodefense drugs, novel drugs, and high-value biosimilars (i.e., follow-on biologics or generic biopharmaceuticals) using its patented StableFast™ Biomanufacturing Platform, the optimal choice for bringing these products to market with faster, lower cost, superior-quality manufacture. For over 10 years, BioFactura has been advancing life-saving medicines from the research bench to the patient using its innovative drug development and manufacturing technologies. Current and past programs include biodefense drugs against smallpox and Ebola, novel medicines for cancer, and low-cost/high-quality biosimilars for autoimmune and infectious diseases.

Biological Mimetics, Inc. (“BMI”) was formed to commercialize innovative pharmaceutical products that will improve the quality of life and overall state of public health by combating resistant and emerging diseases in human and veterinary medicine. Our mission philosophy is to remain a creative and innovative biotechnology firm dedicated to improving the quality of life and overall state of public health through the application of novel technologies for the development and commercialization of human and veterinary biologics to address a long list of hitherto intractable disease targets involving viruses, bacteria, parasites, and cancer. As a result of BMI’s elucidation of “Deceptive Imprinting,” a mechanism of antigenic variation used by microbial pathogens and cancer cells to evade the host immune system, BMI developed “Immune Refocusing Technology” to circumvent such evasion mechanisms. Through the application of IRT, BMI strives to: (1) generate vaccines against pathogens for which no effective vaccine exists and (2) improve upon current strain-limited or serotype-limited protection of commercially available human and veterinary vaccines. IRT is able to alter the natural antigenicity and immunogenicity of targeted protein antigens making it a valuable tool to induce and select monoclonal antibodies. IRT can also be utilized to immune dampen therapeutic proteins and biologics to improve biological half-life and safety profiles.

Biologics Resources, LLC (BRLLC) is a Vaccines, immunotherapeutics and Biopharmaceuticals technology company.

BioMarker Strategies has developed the proprietary SnapPath® Cancer Diagnostics System for predictive tests to guide targeted drug development and treatment selection for patients with solid tumor malignancies. Our mission is to make personalized medicine more of a reality for these patients. SnapPath® is unique in automating and standardizing functional ex vivo profiling to capture the dynamic and predictive signaling information available only from live solid tumor cells. Our PathMAP® Functional Signaling Profiles, created using the SnapPath® system, represent a new class of biomarker tests that are highly predictive of individual response to targeted treatments for solid tumors, because they are based on information available only from live cells. Our business development efforts are directed toward entering into funded collaborations with companies developing targeted therapies for patients with solid tumors. The capabilities of SnapPath® and the Functional Profiles it enables are available for Research Use in preclinical studies in tumorgraft and other model systems, and in early clinical studies to assess pharmacodynamic changes in the solid tumors of individual patients.

BiomX (NYSE America: PHGE) is developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.

BiOneCure Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative ADC drugs for the treatment of cancers. The company was founded in 2017 by a group of industry veterans who have worked in global biopharmaceutical companies. Their research focuses on creating innovative technology platforms and adopting a multifaceted approach to develop new medicines that exceed current standards. The current pipeline covers classic ADCs, bispecific ADCs, and bifunctional ADCs, aiming to be the first-in-class or the best-in-class products.

BIOQUAL, Inc. is fully accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care International (AAALAC) and has a long history of providing state-of-the-art facilities and trained, experienced research scientists, veterinarians and animal care personnel for clients involved in infectious disease investigations, cancer research, and a wide variety of other in vivo and in vitro studies.

We help scientists solve disease, develop drugs, and extend healthspan by building tools that simplify R&D, simulate biology, and untangle the complexity of life. Streamline computational analysis today. Discover drugs tomorrow.

Medical device design and development. First patented product under development is BondTrue, which standardizes surgical closure for better wound healing. Unlike other closure techniques, BondTrue knows where the incision was made so it can precisely realign the wound back together, reducing wound complications, saving time and costs.

BrainCool Inc is an innovative medical device company that develops, markets, and sellsleading medical cooling systems for indications and areas with significant medical benefitswithin the healthcare sector. The company focuses on two business segments, Brain Coolingand Pain Management.

BrightWave makes photobioreactors designed to provide the ideal growth environment, whether your goal is maximizing overall growth rates and densities, maintaining cultures at set parameters, or applying stress factors to enhance metabolite production. The photobioreactors control lighting, pH, temperature, and nutrient delivery.

BullFrog AI (NASDAQ: BFRG) is a technology-enabled life science company using advanced artificial intelligence (AI) to usher in the next generation of lifesaving therapies. With our leading-edge platform, bfLEAP™, we aid in accelerating and de-risking drug discovery and clinical development using one of the industry's most advanced graph analytic AI technologies. The Problem: The drug development landscape is littered with failed products and unrealized ROI — all while patients are desperately waiting for treatments that often don't come: • The cost of bringing a drug to market is $.8 to $2.8 billion • Almost 90% of drugs don't get there • The average time to market is 8.5 YEARS Our Solution: We're applying machine learning and AI in drug development to identify new potential therapeutic targets, optimize clinical trials, rescue and repurpose drugs for new indications, and discover new drug targets. By identifying hidden relationships in clinical data, we aim to mitigate risk and elevate the trajectory of precision medicine. Our Technology: The bfLEAP™ platform delivers in a way that neural network models cannot: Explainable AI. We use network models in an interactive graph machine learning format to display and explain your data insights with confidence. Say goodbye to "black box" processing and say hello to AI outputs you can explore and understand. Join Us in Our Mission: With our platform's superior capabilities, a high-powered team of industry experts, and a pipeline of exclusive in-licensed assets for clinical development, BullFrog AI is pushing the boundaries of AI-assisted drug development. Make BullFrog AI an extension of your organization and clear your analytical barriers. Leap into the next generation of drug development with BullFrog AI.

Cartesian Therapeutics is a fully integrated, clinical-stage biopharmaceutical company developing novel cell and gene immunotherapies to treat cancer and autoimmune diseases.

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical products and various therapeutics in China, the United States, and internationally. The company’s product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Its product pipeline also comprise CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma; CID-103, an anti-CD38 monoclonal antibody being for the treatment of patients with multiple myeloma; ZEVALIN, a CD20-directed radiotherapeutic antibody, to treat patients with NHL; and Thiotepa, a chemotherapeutic agent, which has multiple indications including use as a conditioning treatment for use prior to hematopoietic stem cell transplantation. In addition, the company offers MARQIBO, a microtubule inhibitor, approved by the FDA for the treatment of adult patients with Philadelphia chromosome-negative ALL; and Octreotide LAI formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumours, as well as developing a portfolio of 25 FDA-approved abbreviated new drug applications. It has licensing agreements with Black Belt Therapeutics Limited; Juventas Cell Therapy Ltd.; Pharmathen Global BV; and Cleave Therapeutics, Inc. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is based in Rockville, Maryland.

Cellex has developed a rapid test for IgG and IgM antibodies to SARS-CoV-2. The company hastests that detect antibodies to multiple kinds of pathogens including HIV, HCV, Syphilis, HSV, and also makes tests for diabetes.Cellex received emergency use authorization (EUA) for its COVID-19 antibody test from the FDA for qSARS-CoV-2 IgG/IgM Rapid Test in 3/2020

Cellomics Technology, LLC is dedicated in developing more efficient and powerful tools to enhance and accelerate life science researches. Top scientific excellence is the goal and focus of our scientists.

Cellphire Therapeutics, Inc. is a Rockville, Maryland-based biotechnology company developing next-generation therapeutics. The company is applying its proprietary cell stabilization technology to all cell types, including platelets, to develop lifesaving products. Its lead product, Thrombosomes®, a freeze-dried hemostatic agent derived from human platelets, is currently in a Phase I clinical trial. Cellphire’s technology has potential applications across a wide range of medical applications from trauma to wound care, imaging, targeted drug delivery, and regenerative medicine.

CentryMed is a biopharmaceutical company located in Frederick, Maryland, neighboring the National Cancer Institute (NCI) and numerous pioneering biotechnology companies and supporting entities. Since its founding in 2018, CentryMed has been dedicated to discovering and developing safer and more effective biotherapeutics for the treatment of various diseases.

Cerium Pharmaceuticals is dedicated to creating efficacious therapies for patients with kidney diseases. Cerium is currently focused on developing the first drug approved for a very rare kidney disease called Primary Membranous Nephropathy (PMN). There are approximately 75,000 PMN patients in the US and approximately 3,000 newly diagnosed PMN patients per year.

CirrusDx, Inc. is an infectious disease company with a CLIA certified lab that offers unique testing solutions for UTI, STI, and Respiratory Infections (among others) that are tailored to Long Term Care, Geriatrics, Urology, Uro-Gynecology, OBGYN and various specialty/general practice clinics. Our UTI test provides complete results in 24-48 hours, identifying uropathogens and offering antibiotic recommendations to aid in individualized patient treatment. CirrusDx is bringing diagnostic tools closer to the patient to counteract the challenge presented by antibiotic stewardship and empirical treatment.

CiVi Biopharma Inc. is a US-based, privately-held biopharmaceutical company, founded in 2016. The Company's research and development activities are focused on creating novel therapies for cardiovascular, metabolic and related diseases. CiVi’s innovative pipeline includes CiVi007, a long-acting PCSK9 third-generation Locked Nucleic Acid antisense molecule being developed for the treatment of hypercholesterolemia and the prevention of cardiovascular disease. In addition, the Company currently has other clinical stage development program activity aimed at treating severe liver diseases.

Clear Guide Medical is a leader in next-gen medical imaging fusion and navigation technology. Our vision-based approach has been introduced in a family of clinical guidance products, including the CLEAR GUIDE SCENERGY for instrument guidance and SCENERGY FUSION for ultrasound and CT/MRI image fusion. Our products make minimally-invasive interventions like biopsies, ablations, pain injections, and peripheral nerve blocks efficient and cost-effective. The company is a privately-held spinout of the Johns Hopkins Medical Institutions and The Johns Hopkins University based in Baltimore, Maryland.

Introducing CLR, a simple solution for suction and irrigation through indwelling catheters such as chest tubes. The patented CLR Irrigator is an ergonomic suction/irrigator that empowers easy, one-handed lavage and evacuation of fluid collections such as hemothorax. Our unique CLR Port can stay attached to the indwelling catheter, allowing standard drainage as well as clean access for repeated/delayed lavage without breaking the drainage circuit. When it comes to thoracic irrigation, the solution is cl__r!

CNBX Pharmaceuticals is a publicly traded company (CNBX: OTCQB) and developer of the world's first cannabinoid-based antitumor drug candidate for the treatment of colorectal cancer based on the company's novel and proprietary formulation CNBX™️ RCC-33.

CoapTech is bringing a series of breakthrough medical devices to worldwide markets, leveraging a patented, disruptive platform technology called the Point-of-care Ultrasound Magnet Aligned (PUMA) System. The PUMA Platform will disrupt multiple medical procedures, reducing health care costs, and improving efficiency, safety, quality, patient experience, and access to services around the globe. Invented by Dr. Steven Tropello, a Johns Hopkins-trained critical care physician, the PUMA System enables diagnostic, interventional and therapeutic procedures in hollow organs. The system combines magnetic attraction for device placement guidance, and ubiquitous, low-cost, point-of-care ultrasound for visualization in hollow cavities. Our lead device, the PUMA-G, selected because of its low risk, clear FDA pathway, and strong commercial viability, is for the insertion of Gastrostomy (feeding) tubes. PUMA-G enables a point-of-care (i.e. bedside, as opposed to operating room) procedure for inserting gastrostomy tubes which can be quickly and easily performed by non-surgical providers. By eliminating specialty suites and specialist consultants, PUMA-G will save hospitals money and improve efficiency and safety for this common procedure. PUMA-G has been validated in human anatomy, and has a streamlined regulatory pathway based on FDA presubmission feedback.

Cognate BioServices is a leading contract development and manufacturing organization specialized in cell and cell-mediated gene therapies. We pride ourselves in the level of quality and experience we bring to the table. Cognate is a dynamic, results-driven, organization focused on providing the broadest range of commercialization services to regenerative medicine, cellular immunotherapy and advance cell therapy companies, organizations and institutions. Cognate provides a unique combination of custom services to companies across all points of clinical and commercial development ranging from early preclinical studies, to mid phase trials and product scale-up though later stage clinical trials and bridging into commercial manufacturing. Cognate applies the know-how and expertise of its business, scientific and technical teams to successfully develop autologous and allogeneic products across multiple cell-based technology platforms from start to finish.

CHCFbrain.org is a non-profit organization and advocacy group, centered around neuro-development with focus on long-term solutions. The long-term goals, which are the focus of CHCF , are to promote research to 1) identify the root cause(s) of serious learning disabilities and neuro-developmental delays and disorders with mental health manifestations; 2) develop objective unbiased "blood based" diagnostics; 3) develop curative therapies based on these not yet identified or characterized genetic and epigenetic markers. Hypothesis: A common set of gene(s) are involved in diseases of brain including Alzheimer's, Parkinson's, Autism, learning disabilities & neurodevelopmental delays and serious mental health conditions. Mission Statement: To accelerate research in biomarkers for early diagnosis of high risk conditions that affect brain function and to develop novel targeted curative therapies based on molecular causes of these conditions discovered through epigenetic and genetic research. To provide parents and health care professionals objective tools to support development of children very early on as infants and toddlers based on objective behavioral and psychological assessments. We are born with inherent characteristics that define our personality and who we are. Some of us learn to thrive and some of us struggle to master and learn how to cope with our environment. For the majority of us this is not because we have mental health conditions but it is because we are not equipped to thrive in the environment we live in. We at CHCF believe that each person is very unique. We also believe that in order for our children to thrive emotionally we must have objective diagnostic tools that could identify 1) the optimal thriving environment for each child early on and; 2) how each child can learn critical skill sets to cope with inevitable adverse events in the existing global environment. To do so this requires a new approach in understanding who we are. Please join us!

CosmosID provides award-winning, end-to-end microbiome solutions. They offer NGS, Metabolomics, Bioinformatics, as well as the world's most advanced microbiome analysis software, CosmosID-HUB: Microbiome. The HUB relies on validated databases and algorithms specifically designed for maximum sensitivity, precision and lowest false positive rates. Unlike other solutions, CosmosID delivers strain-level results – we understand that the biologically informative and actionable unit in microbiology is not a genus or species, but ultimately a strain and its unique genetic and metabolic properties. CosmosID was founded in 2008 by Dr. Rita Colwell, former director of the National Science Foundation and currently Distinguished University Professor at the University of Maryland and Johns Hopkins University Bloomberg School of Public Health. To learn more please visit www.cosmosid.com.

CraniUS' mission is to invent and engineer world-class technology to define the future of diagnostics and treatments for neurosurgical patients with brain disease. CAUTION – The NeuroPASS device is an investigational device limited by Federal (or United States) law to investigational use and is not available for commercial distribution.

Creatv MicroTech's mission is to dramatically reduce global cancer mortality through early detection. Our innovative blood test can detect cancer in the earliest stages, even before symptoms. It can also confirm whether a patient is responding to treatment and surveil for early signs of recurrence after treatment has finished. Clinical application of this highly sensitive and specific test will improve cancer treatment outcomes. Cancer touches all of us. Almost 40% of Americans are currently expected to receive a diagnosis of cancer in their lifetime. Over half of these diagnoses occur after significant progression, in stages 3 and 4, making it difficult to achieve successful therapeutic outcomes. Early detection with high accuracy is needed for all major cancers. Nearly 14.5 million Americans are living with a history of cancer, many in remission under surveillance for possible recurrence. Early detection of recurrence enables faster response and improved outcomes. Our CellSieve diagnostic platform uncovered a previously unknown cell in the blood of cancer patients, the cancer associated macrophage-like cell (CAML). These cells are very large and distinctly different from normal cells and circulating tumor cells (CTCs). We found these CAMLs in patients with solid tumors, but not in healthy individuals. CAMLs are highly informative, because they contain markers of the cancer type and indicate sensitivity or resistance to particular treatments. Unlike CTCs, CAMLs are found in all stages of cancer, including stage I. Together, CAMLs and CTCs provide a unique capability for early detection of cancer, monitoring treatment, and watching for recurrence. CellSieve is currently in research use at leading cancer clinics in the US and eight foreign countries.

CSSi LifeSciences™ Drug & Medical Device Commercialization & Medical Device CRO Our goal is to ensure a successful and expeditious pathway to commercialization for our clients’ drugs and medical devices by providing insight-driven analysis that saves time, development costs, and resources. We enable faster, more informed decision making to increase commercial success, while reducing the risk of late-stage failures and post-authorization action. Unparalleled Success from Discovery to Commercialization • Commercialized over 500 new drugs, biologics, medical devices, and in-vitro diagnostics • Over 250 medical device 510(k) Class 1-3 submissions with 100% success. • Extensive Orphan, “First in Class,” and “First In” Indication success. • Reduced time to approval by over 600 days. • Over 100 NDA, ANDA and BLA submissions, with 96% success. • Greater than 60 EMA CHMP Marketing Authorizations. • SmartStudyTM design and feasibility assessments enhanced study efficiency and success and reduced protocol amendments by over 50%. CSSi LifeSciences Medical Device CRO has experience navigating regulations in over 100 countries. Often companies struggle with the pathways for a medical device from design to commercialization because of the ambiguity and complexity of the process. Regulations and requirements change frequently and vary by notifying bodies, country, level of risk (i.e., Class 1-3), specific product claims, and intended use. Our diverse team has many years of medical device commercialization experience, with the knowledge that goes beyond published guidance, documents and initiatives. CSSi LifeSciences Medical Device CRO aims to impact the timeline of regulatory clearance and increase profitability.

Our brand name and formulations amalgamate the knowledge of modern research in dietary supplements and the traditional wisdom of Indian system of medicine- Ayurveda. Cureveda’s innovative formulations are supported by knowledge and established trust which Baidyanath - pioneers in herbal formulations, has accumulated since 1917. Cureveda will provide you solutions for digestive issues, bone and joint care, arthritis, hair & skin health, sexual wellness, immunity, urinary & kidney healthy, liver health etc. and address ways for you to be fit body, mind and soul.

The Cystic Fibrosis Foundation is the world’s leader in the search for a cure for people with cystic fibrosis, a rare, genetic disease in which a defective gene causes a thick buildup of mucus in the lungs, pancreas, and other organs. The buildup of mucus can lead to extensive lung damage, respiratory failure, malnutrition, liver disease, and gastrointestinal issues, among many other complications. Recognized globally, the Cystic Fibrosis Foundation has led the way in the fight against cystic fibrosis, fueling extraordinary medical and scientific progress. Working alongside the CF community, the CF Foundation has fostered the development of more than a dozen CF treatments — an unprecedented number in a short span of time — and helped add decades of life for people with CF. Thanks to this work, the life expectancy of someone born with CF has doubled in the last 30 years. We are driven by a dream that one day every person with cystic fibrosis will have the chance to live a long, healthy life. Our vision is a cure for every person with cystic fibrosis and a life free from the burden of this disease. While our headquarters are in Bethesda, Maryland, we have additional offices in more than 60 locations across the country with positions in fundraising, marketing, digital, information technology, legal, finance and more – all supporting our mission to cure cystic fibrosis. At the Foundation, we are committed to creating an environment that is free from discrimination and provides a rewarding experience for all members of our team. We strive to be an organization where everyone is welcomed and where talented individuals from all backgrounds have the opportunity to thrive. The CF Foundation is a nonprofit, donor-supported organization and an accredited charity of the Better Business Bureau's Wise Giving Alliance. Please visit us at www.cff.org.

D&D is a clinical-stage global biotech company that focuses on development and commercialization of revolutionary medicines with the potential to change the lives of patients with unmet medical needs. Our success is built on a product pipeline originating from top research centers.

Deka Biosciences, Inc., is an early-stage biotechnology company focused on generating the next generation targeted cytokine therapies to treat cancer and inflammatory diseases. Deka is developing the dual cytokine, (DiakineTM) platform. Diakines are comprised of optimized, stimulatory, or suppressive disease specific IL-10 variants coupled to other stimulatory or suppressive cytokines via a T1/2 life extending tissue targeting, non-immunogenic scFv technology.

DELFI uses artificial intelligence and whole genome sequencing to sensitively detect unique patterns of DNA fragmentation in the blood of patients with cancer.

A DK Diagnostics®, fundada em 2004, é fabricante exclusiva do Sistema Parasitológico PARATEST®, reconhecido pela Organização Mundial da Saúde (OMS) como uma das 8 tecnologias mais inovadoras do mundo. Com objetivo de fornecer soluções definitivas para a área diagnóstica, a DK é uma empresa global que possui produtos presentes em mais de 35 países ao redor do mundo e com mais de 45 milhões de testes vendidos.

DNA Diagnostics Center is a biotechnology company that specializes in paternity DNA testing and forensic DNA analysis.

DNA Technologies presents a unique anti-counterfeiting and brand protection solution to the marketplace through its combination of synthetic, DNA-laced security markers. We are dedicated to helping manufacturers, authenticators, license & trademark holders, governments and publishers worldwide eliminate the production and distribution of counterfeit goods. DNA Technologies uses expert knowledge to construct unique, synthetic DNA sequences that can encode company and product-specific information into inks, dyes and resins, to provide the ultimate security marker – the DNA MatrixTM. DNA Technologies has become the recognized leader in providing security marking and unequalled protection for valuable products, brands and intellectual property. This patented and proprietary technology has been used to protect the products and brands of Thomas Kinkade, Major League Baseball, the National Hockey League, the Super Bowl, Hanna-Barbera, BRL Hardy's Wines and the 2000 Sydney Olympics.

DP Clinical, Inc. is a privately held Contract Research Organization (CRO) specializing in neurology/CNS (including spinal cord injury), oncology, ophthalmology, infectious disease/vaccines, and rare disease Phase I-IV clinical programs. DP Clinical provides a full complement of clinical trial services to pharmaceutical, biotech, and medical device companies including trial management, monitoring, data management, biostatistics, regulatory, safety monitoring and reporting, and medical writing. Since 1994, we have worked for clients of all sizes — small to large pharmaceutical and biotech companies, academic research institutions, and government sponsors. DP Clinical provides integrated trial solutions as well as specific service components based on sponsor need. Our comprehensive services include: • Project management • Clinical trial monitoring • Data management • Biostatistics • Pharmacovigilance and safety • Regulatory affairs • Quality assurance • Medical writing

We're building scalable low-cost, high-performance diagnostics for infectious disease in communities, starting with Tuberculosis. Our mission is to create large scale diagnostics that can be used to test large samples such as those from food, water, environments and air to prevent infectious disease outbreaks. For all 7 billion of us.

GDIT is a global technology and professional services company that delivers consulting, technology and mission services to every major agency across the U.S. government, defense and intelligence community. Our 30,000 experts extract the power of technology to create immediate value and deliver solutions at the edge of innovation. We operate across 30 countries worldwide, offering leading capabilities in digital modernization, AI/ML, Cloud, Cyber and application development. GDIT is part of General Dynamics, a global aerospace and defense company. We have shared our clients’ sense of purpose for over half a century and have a have a unique understanding of their missions, complex environments, and a rapidly changing world. Together with our clients, we strive to create a safer, smarter world by harnessing the power of deep expertise and advanced technology.

EdgeBio has a team of experienced research professionals that are knowledgeable in next generation sequencing technologies and applications. From library preparation through data analysis, EdgeBio representatives are there to discuss your project on a custom basis to ensure that you receive the results you need for your research. Follow us on Twitter at: https://twitter.com/EdgeBio

Elixirgen Scientific is a global leader in regenerative medicine and biotechnology, headquartered in the Science + Technology Park at the Johns Hopkins Medical Campus in Baltimore, MD. Our mission is to advance science and medicine with fast, functional, and scalable induced pluripotent stem cell (iPSC) differentiation products and services. Our state-of-the-art, transcription-factor-based technology allows you to overcome the high cost and inefficiencies associated with lengthy cell differentiation periods. We empower research institutions, pharmaceutical organizations, and biomedical enterprises worldwide, even those with no previous iPSC experience, by increasing access to relevant cells for modeling human biology and accelerating the path to drug discovery and development. This commitment to innovation and efficiency underpins our goal to revolutionize regenerative medicine. We are the partner of choice for supplying high-quality, reliable iPSC-derived cells and kits and conducting customized research services. Connect with Elixirgen Scientific today to discover how we can accelerate your research!

Elixirgen Therapeutics is a biotechnology company advancing its controllable self-replicating RNA technology to develop therapies for a broad spectrum of diseases, including rare diseases, aging-related disorders, and cancer. Elixirgen Therapeutics is located in the Science + Technology Park at Johns Hopkins in Baltimore.

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. The company also provides NARCAN for the emergency treatment of known or suspected opioid overdose; Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin; and Trobigard a combination drug-device auto injector product candidate. In addition, it offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; CHIKUNGUNYA, a chikungunya virus-like particle vaccine; and ADENOVIRUS 4/7. Further, the company offers other discovery and preclinical product candidates addressing PHTs, including viral hemorrhagic fevers caused by Ebola, Marburg, Sudan, and Lassa viruses; diarrheal disease caused by Shigella; and heat-labile toxin producing enterotoxigenic Escherichia coli, etc. Additionally, it offers FLU-IGIV to treat Influenza A infection; and ZIKV-IG, a prophylaxis for Zika infections, as well as contract development and manufacturing services to pharma and biotech industries, and government agencies/non-governmental organizations. The company has collaboration agreements with Novavax Inc.; and Johnson & Johnson. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.

With over 25 years of experience, EMINENT, headquartered in Maryland, is a specialist in offering comprehensive services for pharmaceutical drug development and clinical management. Our services extend across the full development spectrum, from the initial characterization of bulk drugs to the final product launch. We are adept at supporting pharmaceutical and biotechnology companies, as well as academic institutions and Contract Research Organizations (CROs), by providing customized solutions to meet a variety of needs. These needs include drug formulation, stability testing, clinical manufacturing, patient-specific packaging, randomization, distribution, monitoring of drug products at clinical sites, patient compliance tracking, return drug accountability, and the storage of biological specimens.

EMIT Imaging is the leading manufacturer of CFT systems and provider of CFT fee-for-service research for the global life sciences market. CFT was created to better visualize drug distribution and protein expression (pharmacokinetics/PK, and pharmacodynamics/PD) in whole animals at high resolution and sensitivity. CFT applications span drug discovery and delivery, oncology and immunotherapy, gene and cell therapy, neuroscience, and beyond. The company is based in Baltimore, MD, and Boston, MA.

埃格林医药是一家高速发展的国际化生物医药公司，以“关注临床迫切需求，惠及全球广大患者”为使命，致力于在全球范围内的临床研发与商业化推广

ExeGi Pharma is a biotechnology company focused on the development and commercialization of live biotherapeutic and probiotic medicines. Our team leverages the field of microbiome science to deliver novel, clinically supported, live biotherapeutic and probiotic treatments for a variety of unmet medical needs for both humans and veterinary applications. Makers of Visbiome and Visbiome Vet high potency probiotics.

Eyedea Medical develops new technologies to address the evolving needs of patients, corneal specialists, and eye banks. We provide affordable, high-quality products to improve the efficiency, quality, and accessibility of corneal transplants.

"EzBiome, Inc. is a microbiome company promising the discovery of exciting new biology and transformative therapeutics through data- and database-driven microbial taxonomy, new bacterial species concept and standard, and the use of carefully curated and expert validated reference database that includes >3,000 new species. We cater world-class sample to discovery services on microbial identification, microbial genomics, microbiome bioinformatics, and database expertise for businesses worldwide for regulated and non-regulated applications to shorten the time for microbiota-based discovery and development of therapeutics and companion diagnostics for microbiome-related diseases."

Fina Biosolutions, LLC was founded in 2006 by Dr. Andrew Lees with an initial focus on helping emerging market vaccine manufacturers learn to make affordable conjugate vaccines. The company offers bioconjugation, protein expression, purification, immunoassay design, analytics, training, and consulting services.

The Food and Drug Administration is an agency within the Department of Health and Human Services. The FDA is responsible for protecting the public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices; and by ensuring the safety of our nation's food supply, cosmetics, and products that emit radiation. FDA also has responsibility for regulating the manufacturing, marketing, and distribution of tobacco products to protect the public health and to reduce tobacco use by minors. FDA is responsible for advancing the public health by helping to speed innovations that make medical products more effective, safer, and more affordable and by helping the public get the accurate, science-based information they need to use medical products and foods to maintain and improve their health. FDA also plays a significant role in the Nation's counterterrorism capability. FDA fulfills this responsibility by ensuring the security of the food supply and by fostering development of medical products to respond to deliberate and naturally emerging public health threats.

Forever Oceans is pioneering a new way to produce delicious, natural seafood that's good for people and the planet. We combine our expertise in off-shore aquaculture with unique innovations to ocean-raise fish that are always delicious, healthy, and sustainable.

Products for Third World

Fzata, Inc. is a oral biologics biopharmaceutical company based in Halethorpe, MD within the vibrant BioHealth Capital Region. Fzata’s vision is to reduce health inequities by expanding patient access to therapeutic biologics. This is made possible with our proprietary first-in-class oral Bioengineered Probiotic Yeast Medicines (BioPYM™) platform. BioPYM enables orally administered yeast micro-factories to make biologic therapeutics “on-site” in the gut for treatment of GI disorders like infectious diseases, inflammation, metabolic diseases, (e.g., diabetes), colon cancer, and more. Our oral biologic drug candidates are intended to help patients that inject biologic medicine by 1) offering affordable, non-refrigerated, convenient oral capsules, 2) improving quality of life with no needles and no need for health-care administration and 3) improving patient outcomes with expected high safety and high efficacy targeted to GI.

Gain Therapeutics, Inc., a development stage biotechnology company, develops various therapeutics to treat diseases caused by protein misfolding. It focuses on lysosomal storage disorders, such as rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover novel allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites and restore protein folding treating the underlying disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson’s, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.

Galen Robotics is developing a single-platform solution to aid surgeons across several disciplines with minimal disturbance to existing workflows. Our cooperative control paradigm aims to eliminate hand tremor and enable surgeons to realize precise minimally invasive interventions in otolaryngology, head and neck surgery, and tissue reconstruction that were previously considered beyond human capacity.

At GeneDx, we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world’s largest rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It all starts with a single test.

Georgiamune Inc. is a private, science and discovery clinical stage immunotherapeutic biotechnology company focused on reprogramming immune signaling pathways to redirect the immune system to fight diseases. Unique approaches to re-establishing immune balance and groundbreaking scientific discoveries have led to the development of pioneering immune therapeutics for cancer and autoimmune diseases.

Gliknik is a privately held biopharmaceutical company working to ease human suffering by creating new therapies for people living with immune disorders.

GlycoMimetics is an oncology-focused biotechnology company. We are dedicated to improving the lives of patients by discovering, developing and commercializing novel, small-molecule glycomimetic product candidates.

Developer of oral, gut-targeted polymer therapeutics for the treatment of metabolic indications such as type 2 diabetes, and other chronic conditions. The company is developing a lead drug, which is orally administered, non-absorbed, gut-restricted duodenal exclusion therapy designed to replicate the metabolic effects of bariatric surgery with safety-advantages avoiding invasive complications of surgeries and procedures.

In April 2024, Deloitte acquired substantially all of the assets of Gryphon Scientific LLC. The team, comprised of life scientists and health researchers who apply rigorous scientific analysis to problems of global health and homeland security, is now part of the Deloitte GPS Federal Health sector. Our projects drive policy changes in security, preparedness, and science policy at the highest levels of US government.

Harford Community College is a vibrant, open-access institution located on 352 scenic acres in Bel Air, Maryland. We offer more than 150 degree, workforce training, career advancement, and personal interest programs and provide art, entertainment, and athletic events for our entire community. When you choose Harford, you choose to invest in yourself—and you do so knowing you have the full support of faculty and staff who will walk beside you every step of the way to help you succeed, no matter who you are or what goals you have.

Haystack MRD™ by Quest Diagnostics is a tumor-informed, next-generation minimal residual disease (MRD) test that detects ultralow levels of circulating tumor DNA (ctDNA) to uncover residual disease after cancer treatment. Based on more than 20 years of clinical development and technology from pioneers in cancer genomics at Johns Hopkins University, Haystack MRD's purpose-built, high-precision science delivers novel insights that can help inform treatment decision-making.

Hememics uniquely uses graphene-based sensors with our patented bio preservatives to bring handheld, lab-quality testing performance to wherever needed – whether it is a farm, emergency room or battlefield. Our rugged, low-cost platform consists of a portable, easy-to-use reader utilizing a single-use biochip with 32 sensors. Our sensors can be individually programmed to detect molecular, antigen and antibody targets. We put a whole lab in your hand so you can make decisions when and wherever necessary – simplifying workflows with results within minutes.

Howard Hughes Medical Institute is a biomedical research organization focusing on advancing medical and life sciences research.

HypOxygen® was founded to provide technology with the level of precision and accuracy necessary for scientific study and research. We specialize in hypoxic chambers (or low oxygen incubators) for scientists focusing on cell research applications requiring precise atmospheric conditions that can be accurately controlled. Unlike a commonly used CO2 incubator, our hypoxia workstations can achieve these precise conditions.

Headquartered in North Bethesda, Maryland, Ibex Biosciences, Inc. ("Ibex") distinguishes itself in the early-stage biotech sector with its varied research and development approach. ​Ibex boasts a diverse portfolio that includes therapeutic antibodies, gene therapies, and regenerative medicine programs. We are proud of our proven capacity to discover and validate potential therapies from scratch, thus eliminating the need for external technology acquisitions or in-licensing. Our accomplishments are underscored by a series of in-vivo studies, which have delivered remarkable efficacy against a range of challenging medical conditions.

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the Universal Intracellular Targeted Expression (UNITE) nucleic acid immunotherapy platform. This investigational technology has the potential to alter how we use immunotherapy for a number of diseases, including cancer, allergy and infectious diseases.

ImQuest BioSciences is a preclinical contract research and development organization (CRO) that provides services to evaluate the potential of new and novel pharmaceutical products for the treatment and prevention of viruses, bacteria, cancer and inflammatory diseases. As part of our ImQuest SUCCESS platform, we provide expert preclinical research services, including compound screening to define compound efficacy and drug target validation analysis to define the mechanism of action and toxicity of pharmaceutical products. We specialize in the development of small molecules, natural products, biologics, antimicrobial peptides, therapeutic antibodies and vaccines for infectious disease and cancer drug development programs. Our preclinical contract research services are comprised of interrelated efficacy-defining components for infectious disease (including microbiology and virology), cancer and women's health with parallel evaluations of in vitro and ex vivo toxicity and the pharmaceutical properties and chemical structure of preclinical candidates to efficiently validate you drug target. We are committed to earning our client's trust and building long term relationships through collaboration, unwavering commitment to quality science and consistent and effective communication. Our team has decades of experience in the field of virology, microbiology and oncology. As such, we understand that each product and each client is unique and we strive to provide effective solutions.

Infinity Bio is a technology company that provides detailed insights into the immune system using its proprietary antibody profiling platform. The company’s core technology comprehensively measures the antibody reactome, revealing the targets of individual immune responses against all known human viruses, human proteins (autoimmunity), and allergen proteins. Infinity's assay, MIPSA, was developed at Johns Hopkins University in Ben Larman's Lab of Precision Immunology. It builds off decades of work in the fields of genomics, proteomics, immunology, and bioinformatics. Our assay was engineered to enable best-in-class turnaround times and cost. With a team of experienced professionals and a state-of-the-art facility, we are poised to make a significant impact to research and for our customers.

Innovative Cellular Therapeutics (ICT) is a clinical-stage, VC-backed cell therapy company based in Rockville, MD. ICT has established a broad portfolio of CAR-T products to treat cancer patients. Some highlights of the company are provided below: Leading clinical data in solid tumor CAR-T Colorectal cancer: 3rd line treatment, ~50% PR/PMR (8/16) in dose escalation trial Activity in additional solid tumor indication including thyroid and pancreas Significant market opportunity in colorectal cancer and other solid tumor cancers Lead program in colorectal cancer: Estimated 53,2001 deaths (#2 cancer death) in the U.S. in 2020 Platform technology for solid tumors, which comprise 91% of new cancer cases Strong global IP protection CoupledCAR®, ArmoredCAR®, and other ICT technologies protected by ~200 patents/patent applications globally, including for U.S., Europe, China and Japan

Intralytix, Inc. is a biotechnology company focused on the discovery, production and marketing of bacteriophage-based products to control bacterial pathogens in environmental, food processing, and medical settings. The company makes phage that target E. coli, Salmonella, and Listeria in pet and human food.Intralytix has developed and is continuing to develop phage preparations for preventing and treating bacterial diseases of pets and other animals, including agriculturally-important animals. Other products include phage mixtures as probiotics.Intralytix’s is also developing phage preparations for treating infected wounds.

Our mission is to develop a superior vaccine platform to improve clinical outcomes for cancer patients.

IZI Medical is a prominent medical device manufacturer and distributor, specializing in minimally invasive diagnostic and therapeutic solutions. Founded in 1991 by a neuroradiologist and a radiation oncologist, the company is headquartered in Baltimore, Maryland. In 2022, IZI became part of Halma plc, operating as a standalone entity within Halma’s Healthcare sector. The company is dedicated to enhancing patient care through physician-inspired innovations and aims to improve the quality of life for patients. IZI Medical offers a diverse portfolio of 44 medical devices across four key markets: image-guided surgery, interventional oncology, interventional neuro and spine, and radiation therapy. Their products include tools for instrument navigation, tumor localization, and treatment planning systems. With over 100 active patents, IZI Medical emphasizes innovation in minimally invasive procedures. The company serves more than 2,500 hospitals in the U.S. and distributes its products to physicians in 35 countries, focusing on improving clinical efficiency and patient outcomes.

Johns Hopkins Medicine is a governing structure for the University’s School of Medicine and the health system, coordinating their research, teaching, patient care, and related enterprises. The Johns Hopkins Hospital opened in 1889, followed four years later by the university’s School of Medicine, revolutionizing medical practice, teaching, and research in the United States. The hospital is now part of the Johns Hopkins Health System, which includes two other acute-care hospitals and additional integrated health-care delivery components, with a network of primary and specialty care practices throughout Maryland, outpatient care, long-term care, and home care. The Johns Hopkins University opened in 1876 as America’s first research university, founded for the express purpose of expanding knowledge and putting that knowledge to work for the good of humanity. Two Interconnected Institutions: Over the years, the University and Hospital have grown, and—sometimes jointly, sometimes separately—they have created affiliated organizations. The Johns Hopkins Institutions is a collective name for the University and the Johns Hopkins Health System. The Johns Hopkins University includes nine academic and research divisions, and numerous centers, institutes, and affiliated entities. Johns Hopkins Medicine is a governing structure for the University’s School of Medicine and the health system, coordinating their research, teaching, patient care, and related enterprises.

Johns Hopkins University is a higher education institution known for its research initiatives and academic programs.

JuneBrain is an early start-up company based in the Washington, DC area. Our mission is to develop a telehealth eye-scanning system that allows clinicians to monitor patients with eye and brain disease outside of the traditional clinical setting, leading to earlier detection of new disease and improved monitoring of treatment efficacy. Though our mission begins in the eye care community, our long-term goal is to extend the use of our device into the broader neurological disease population, thus creating a pathway towards more frequent, widely accessible monitoring of eye and brain health.

At kallisio, we're on a mission to revolutionize head & neck cancer care by safeguarding patients against the harmful effects of radiation therapy. Our 3D printed patient-specific immobilization devices provide unparalleled protection to Organs at Risk (OARs) while allowing radoncs to deliver the highest effective dose of radiation treatment. In collaboration with MDACC, we've pioneered a groundbreaking, scalable, billable, and custom-fit solution for precise patient immobilization and tongue deviation. Our innovation aims to mitigate long-term side effects, including mucositis, xerostomia, and dysphagia. Interested in joining our mission to protect patients from radiation-induced harm?

KaloCyte, Inc., a preclinical biotech that has developed an artificial RBC substitute for use as a lifeline when blood is not available. We are located at the University of Maryland, Baltimore (UMB) as an Affiliate of the UM BioPark. KaloCyte’s offices and labs are sited within the UM School of Medicine’s Center for Blood Oxygen Transport and Hemostasis (CBOTH) directed by Allan Doctor, MD (KaloCyte Co-Founder and CSO). KaloCyte was founded in 2016 by a distinguished team of Washington University in St. Louis researchers in physiology, bioengineering, and trauma care, with support from the BioGenerator Fundamentals program. KaloCyte has demonstrated preclinical safety and efficacy for ErythroMer, a shelf-stable, bio-inspired artificial red blood cell envisioned for use when stored red blood cells are unavailable, undesirable or in short supply. KaloCyte is supported by $14M in federal awards and $5M investor funding. ErythroMer is a first-in-class, bio-inspired nanoparticle-encapsulated human hemoglobin, which mimics the vital oxygen-carrying functionality of RBCs and can be freeze-dried for long-term storage. Erythromer’s synthetic outer membrane, small size and surface area allow for physiologically realistic gas exchange. The synthetic polymer shell is “immune-silent”, inert and carries no blood antigens, eliminating the need to type and cross-match as with stored blood. ErythroMer can be freeze-dried or “lyophilized”, for a much longer shelf life than stored blood. It is covered by issued U.S. patents that specify composition of matter, method of preparation, and use as an oxygen carrier.

Kemp Proteins, LLC (formerly Kempbio) is a privately-owned, USA-based contract research and manufacturing organization located in Frederick, MD. Kemp Proteins is a premier provider of customized solutions for protein-related challenges. We are "Protein Problem-Solvers" focused on delivering best-in-class gene-to-protein services that optimize productivity and mitigate risk for innovators across the life sciences. The company has over two decades of experience in production of proteins and antibodies for use in basic research, diagnostics and drug development at the pre-clinical stage. Core expertise consists of gene-to-protein expression in mammalian, insect, and E. coli, hybridoma and stable cell-line development, analytical protein characterization, and Upstream/ Downstream process discovery/ optimization. Kemp Proteins' Process Discovery Services transition early therapeutic discovery programs to the biomanufacturing phase. Our teams identify key developability markers early in the discovery process while keeping scale and safety in mind. We use Process Analytical Tools in the initial discovery phase to identify the Critical Process Parameters required to derive Upstream and Downstream Processes that ensure Critical Quality Attributes are met. Once unit operations are defined for scale, we generate engineering and tox-material suitable for reference and NHP studies. The final processes are captured in Manufacturing Batch Records enabling seamless transitions to GMP facilities. Kemp Proteins has experience expressing and purifying a wide range of proteins from antibodies to multi-protein complexes and virus-like particles. The company operates under an ISO9001- and ISO13485-certified Quality Management System and the animal care and use program is AAALAC-accredited.

Kennedy Krieger Institute is a healthcare organization that specializes in pediatric care, medical research, and rehabilitation services.

Founded in 1998, Key Tech (www.keytechinc.com) is a high-tech product design and prototyping company located in Baltimore, Maryland. Our clients value our ability to create first-of-a-kind applications and solve challenging technical problems. A diverse mixture of electrical, mechanical, and computer engineers, as well as industrial designers and physicists, we specialize in transforming complex technologies into simple, intuitive solutions. Services Include: Product de-risking, Prototype and Full Scope Development, Industrial Design, Technology Development, Expertise on Demand, and solving the seemingly unsolvable.

At Kolon TissueGene, we are developing advanced cell therapies to target various orthopedic diseases and degenerative disorders.

SeraCare, part of LGC's Clinical Diagnostics Division, enables the promise of precision medicine by advancing the understanding of disease and providing assurance of the diagnostic result. Our innovative tools and technologies not only ensure the safe, effective, and accurate performance of diagnostic assays but also establish a framework for regulating, compiling, and interpreting data from precision diagnostics. Our portfolio includes a broad range of products such as quality control technologies, disease-state specimens and tissues for research and development, processed biological materials, and immunoassay reagents.

We provide the first minimally invasive treatment for benign and malignant masses in pets. By revolutionizing cryotherapy -- used in human medicine for more than 60 years -- we’re bringing human-quality care to man’s best friends. Our novel CryoNeedle system uses focused extreme cold to quickly and easily treat tumors, letting pets skip the scalpel and get back to playtime. After six years of successful research and development, including clinical trials at Johns Hopkins Hospital -- we are now launching our treatment offerings to clinics everywhere!

Leidos is a Fortune 500® innovation company rapidly addressing the world’s most vexing challenges in national security and health. The company's global workforce of 48,000 collaborates to create smarter technology solutions for customers in heavily regulated industries. Headquartered in Reston, Virginia, Leidos reported annual revenues of approximately $15.4 billion for the fiscal year ended December 29, 2023. Leidos was cited for the meaningful work employees perform that is challenging, impactful, and aligned with our customers’ missions as reasons professionals want to work and stay at our company. Leidos has also been named to lists including Forbes’ Best Employers for Diversity, Forbes’ America’s Best Employers for Women, Military Times Best for Vets Employers, and Ethisphere Institute’s World's Most Ethical Companies®. Employees enjoy career enrichment opportunities available through mobility and development and experience rewarding relationships with supportive supervisors and talented colleagues and customers. Employees appreciate our flexible work environment, allowing for and encouraging a true work-life balance. Our professionals are also excited about our Employee Resource Groups, like the Collaborative Outreach with Remote and Embedded Employees (CORE), which strives to create an environment where every employee, regardless of location, feels fully engaged as a valued employee of Leidos. Your most important work is ahead, visit careers.leidos.com for our latest opportunities.

Leukosight is an online pharmacy that offers remedies of the highest quality, low prices, and a fast delivery system.

Lieber Institute for Brain Development is a research institute focused on advancing understanding of brain development and disorders.

Lifeline Cell Technology® (Lifeline) develops, manufactures, and markets the highest quality normal human cells, cell culture media, and reagents for the research marketplace. We take pride in our customer and technical service and will work diligently to assist you with your cell culture requirements. Lifeline is a wholly owned subsidiary of International Stem Cell Corporation, (ISC) (ISCO.OB), a public stem cell therapeutics company based in Oceanside, CA. Lifeline's production and administrative facilities are located in Frederick, MD. Lifeline's customers are scientists working in major research organizations such as pharmaceutical companies, academic and government institutions. Lifeline's specialized products for the culture of normal human cells eliminate the need for each scientist to create his or her own media and reagents or try to adapt "off the shelf" products to the specialized world of human stem cell research. Our modern laboratories and strict quality assurance provide the highest level of consistent value to the research community.

For 45+ years, LKC Technologies has been making functional eye testing simple and practical for busy clinicians. The handheld, portable RETeval® ERG/VEP device aids in the diagnosis and management of ischemic conditions such as diabetic retinopathy, optic nerve conditions, and other retinal dystrophies by providing objective results without corneal contact.

We connect customers with integrated solutions & predictive technologies to ensure they stay ahead of emerging threats. Headquartered in Bethesda, Maryland, Lockheed Martin is a global security and aerospace company principally engaged in the research, design, development, manufacture, integration and sustainment of advanced technology systems, products and services.

Longhorn Vaccines and Diagnostics, LLC is a research company Headquartered out of 7272 Wisconsin Avenue Bethesda, MD 20814 United States. The R&D facility is at 19 Firstfield Rd Gaithersburg, MD 20878.

As a biopharmaceutical company, our team of dedicated individuals is focused on discovering and developing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. Our core scientific expertise is in the field of protein engineering and our product candidates have been created primarily through our proprietary protein engineering platforms, including our DART® bispecific and Fc Optimization platforms. These platforms are generally focused on the creation of antibodies, antibody derivatives, and antibody-like molecules for use as therapeutic agents. We currently have a pipeline of product candidates in human clinical testing, including seven immuno-oncology programs. Our product candidates and platforms have attracted partnerships with leading pharmaceutical and biotechnology companies around the globe.

At Magbio Genomics, we are dedicated to advancing genetic research with cutting-edge products designed to safeguard the integrity of bio-samples while efficiently isolating circulating biomarkers. Specializing in human genetic research, including cancer studies and non-invasive prenatal testing (NIPT), our innovative solutions empower researchers to unlock invaluable insights. At the heart of our operations lies our core platform, enabling seamless nucleic acid sequencing methods such as Sanger and Next Generation Sequencing (NGS) across both manual and automated workflows. Our commitment extends beyond product development; it's about facilitating quality data generation at an accelerated pace and an accessible cost. Driven by our corporate mission, we strive to empower our customers to achieve their research goals efficiently and effectively, propelling scientific discoveries forward with Magbio Genomics by their side.

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients’ lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today’s processes to innovate tomorrow’s solutions. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: three instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as technical and regulatory support, we aim to guide them on their journey to transform human health.

𝘐𝘮𝘱𝘳𝘰𝘷𝘪𝘯𝘨 𝘏𝘦𝘢𝘭𝘵𝘩 𝘛𝘩𝘳𝘰𝘶𝘨𝘩 𝘐𝘯𝘯𝘰𝘷𝘢𝘵𝘪𝘷𝘦 𝘋𝘪𝘢𝘨𝘯𝘰𝘴𝘵𝘪𝘤𝘴. MaximBio's comprehensive in-house capabilities provide you a world-class experience and confidence in our ability to keep costs down and deliver your products in time. At MaximBio, our team of dedicated professionals with over 25 years of expertise work to create a custom-fit, full service program in state-of-the-art facilities to meet all your needs and specifications: • FDA cGMP Registered for manufacture and distribution of medical devices • Compliant with 21 CFR Part 820 for medical devices • ISO 13485:2016 Certified for manufacturing and packaging of medical devices

Medcura, Inc. is a medical device company based in Riverdale, Maryland, founded in 2007. The company specializes in developing hemostatic products aimed at effective bleeding management and advanced wound care solutions for surgical, medical, and consumer markets. Medcura's primary focus is on creating and distributing hemostatic products that utilize a proprietary technology platform. Their offerings include LifeGel™, a flowable gel for surgical procedures; LifeFoam™, a hemostatic agent for traumatic wounds; and RapidSeal, an antibacterial first aid product. Other solutions include Triple R, Medcura Flex, and Surgicura, all designed to control bleeding and promote healing. These products leverage a modified chitosan biopolymer to enhance safety and efficacy. The company has received significant recognition, including five FDA clearances and two FDA Breakthrough Device Designations. Medcura has raised over $47 million in funding from various investors, including government agencies and private organizations.

Biopharmaceutical Company engaged in vaccine development against emerging viruses and biopharma CDMO manufacturing.

Founded in 1995, Meso Scale Discovery (MSD) is a global leader in the development, manufacture, and commercialization of innovative assays and instruments for the measurement of molecules in biological samples. MSD’s proprietary MULTI ARRAY technology enhances medical research and drug development by enabling researchers to profile many biomarkers simultaneously in a single sample without compromising assay performance. MSD’s technology has been widely adopted by researchers in pharmaceutical companies, government institutions, universities, and clinical laboratories worldwide for its high sensitivity, excellent reproducibility, and wide dynamic range. Throughout its history, MSD has continued to evolve its technology platform to enable researchers to solve complex biological questions and, as the Company looks toward the future, it is expanding into clinical applications and the emerging fields of personalized medicine and companion diagnostics.

MIRA1a is being developed to treat anxiety and cognitive decline in the elderly and neuropathic pain without impurities or the adverse side effects of cannabis plant extracts.

We develop first-in-class RNA-based therapies, with lead programs in Head & Neck Squamous Cell Carcinoma (HNSCC) and Facioscalpulohumeral Muscular Dystrophy (FSHD). Our approach to drug design revolves around using genomic patient data to create highly tailored therapeutics – the right drug for the right patient. Our proprietary DREAmiR™ platform utilizes genomic and outcome data from thousands of patients to identify underlying genetic changes that cause their disease, and then creates a novel RNA therapeutic that can directly target and fix that genetic abnormality.

The National Cancer Institute (NCI) is the federal government's principal agency for cancer research and training.

National Institute of Standards and Technology is a government agency that sets standards, conducts research, and promotes innovation in technology and measurement.

NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. Our lead drug candidate, NT-I7, is the only clinical-stage long acting rhIL-7, and is uniquely positioned to address unmet medical needs in Immuno-Oncology and Infectious Diseases such as COVID-19. IL-7 is a fundamental cytokine for lymphocyte development, survival, and memory development. Furthermore, NT-I7 has been shown clinically to have desired PK/PD and safety profiles, making it an ideal combination partner with T-cell targeted therapies as well as vaccines. NT-I7 is being studied in multiple clinical trials and many in collaboration with industry leaders in I-O, including Merck, BMS, and Roche for CPI combination trials. Follow us on X @neoimmunetech

Neu-Ion is the industry leader in the design, installation, and service of high purity water systems. Headquartered in Baltimore, Neu-Ion has provided specialty water systems to top businesses and organizations in the Mid-Atlantic and nationwide. Our specialized expertise embodies 30+ years in business and a century of collective knowledge. As a local, family-owned organization, service to our customers is available 24/7 and we house the only pure water resin regeneration plant in the Maryland/DC area. This allows us to guarantee the quality and integrity of our products. We collaborate with our clients to provide a tailored solution that meets their needs today AND allows for growth into the future. This relationship-driven approach means that every client receives personalized guidance at each stage—design, installation, and maintenance of our water purification systems. We then provide a preventive maintenance plan to proactively maintain each system according to manufacturer's specification. Our experienced technicians have the capability to service and maintain competitive systems/equipment. From the small, single point of use purified water system to the large building centralized water system, we can supply both new systems and service existing systems through our extensive parts inventory. This means reduced downtime and consistent high-quality output… so seamless that you don't even know it's happening. By using Neu-Ion you are getting the thorough design, agile response time, exceptional customer service and in-depth expertise. High purity waters systems… DONE AND DONE WELL Deionization http://www.neu-ion.com/solutions/deionization-ion-exchange Reverse Osmosis http://www.neu-ion.com/solutions/reverse-osmosis Water Softeners http://www.neu-ion.com/solutions/water-softeners UltraViolet Technology http://www.neu-ion.com/solutions/ultraviolet-technology Turn Key RODI http://www.neu-ion.com/solutions/turn-key-rodi-packages

Neuronascent (NNI) is a small corporation, that we believe has an over-sized opportunity to improve the well-being of millions of patients suffering from chronic neurodegenerative disorders that lack any disease-modifying therapeutic options. As we move toward this goal, we have built a strong track record of meeting critical drug-development milestones, which is of importance to investors and future pharmaceutical partners. Using a novel screening process developed by Neuronascent, the Company was able to identify small molecule therapeutics that generated new neurons in the brain and ensured that these new neurons survived to functionality under neurodegenerative conditions. These small molecule candidates proved successful not only on human neuronal progenitors in a lab dish, but showed the same capacity in animal models of chronic neurological diseases. NNI's synthetic therapeutic candidates are optimized and patented. These orally available candidates have been found to be safe in all testing to date. Our lead candidate for Alzheimer’s and potentially for Parkinson’s disease, has completed in first-in-human testing (Phase 1a), with no significate safety concerns for this therapeutic in healthy aged subjects. The Company is based in Clarksville, Maryland, United States.

Neurotron is a medical devices company that specializes in Neurometer CPT electrodiagnostic sensory nerve conduction threshold (sNCT) testing equipment.

New Horizons Diagnostic Corporation manufacturesand developsproducts and offers contract services for the medical, diagnostic, environmental and food testing markets. Products include bacteriophage, testing for medically relevant bacteria, collection kits and diagnostic kits for detecting biothreats such as anthrax, cholera, ricin, staph enterotoxin, Yersinapestis, botulism toxin, and tularemia.

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIM) technology. The company has two product candidates in human trials, including NEXI-001 in acute myeloid leukemia, or AML; and NEXI-002 in multiple myeloma, or MM. NexImmune, Inc. was founded in 2011 and is headquartered in Gaithersburg, Maryland.

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; and NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. NextCure, Inc. has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Northwest Biotherapeutics, Inc. is a development stage biotechnology company focused on discovering, developing and commercializing immunotherapy products that generate and enhance immune system responses to treat cancer. Currently approved cancer treatments are frequently ineffective, can cause undesirable side effects and provide marginal clinical benefits. The Company’s approach in developing cancer therapies utilizes its expertise in the biology of dendritic cells, which are a type of white blood cell that activate the immune system. The Company’s cancer therapies have been demonstrated in clinical trials to significantly extend both time to recurrence and survival, whilst providing a superior quality of life with no debilitating side effects when compared with current therapies. The Company’s platform technology, DCVax®, uses a patient’s own dendritic cells, the starter engine of the immune system. The dendritic cells are extracted from the body, loaded with tumor biomarkers or ‘‘antigens’’, thereby creating a personalized therapeutic vaccine. Injection of these cells back into the patient initiates a potent immune response against cancer cells, resulting in delayed time to progression and prolonged survival. The Company’s lead product candidate is DCVax®-Brain which targets Glioblastoma Multiforme (‘‘GBM’’), the most lethal form of brain cancer. DCVax®-Brain has entered a Phase II FDA-allowed clinical trial, which is designed and powered as a pivotal trial (i.e. a trial from which a company may go directly to product approval). Following this trial, the Company anticipates filing a biologic license application (or ‘‘BLA’’) with the FDA for DCVax®-Brain. DCVax®-Prostate, which targets hormone independent (i.e. late stage) prostate cancer, has also been cleared by the FDA to commence a Phase III clinical trial, which is also designed and powered as a pivotal trial.

Nostopharma is on a mission to revolutionize orthopedic surgery with reduced complication rates for trauma patients, athletes and chronic inflammation victims.

We’re focused on using our proven vaccine technology to protect health by developing our R&D assets and establishing partnerships. We stand strong against infectious diseases and viral threats—our science grounds us, our technology pushes us forward, our commitment inspires us to achieve our mission of ensuring broad access to our vaccines. It’s more than our job. It’s our passion. Our Novavax Social Community Guidelines: https://www.novavax.com/social-media-community-guidelines

Lab-quality, Clinically Actionable Results in Minutes Anywhere! Novel Dx detects the genetic material of pathogens using Nucleic Acid Amplification techniques. These are the same methods that are utilized in large reference laboratories Novel Dx delivers lab-quality results in under 30 minutes so patients can be tested and treated in the same visit

Noxilizer, Inc. provides ultra-low temperature (10°C to 30°C) nitrogen dioxide sterilization technology that offers many benefits over traditional sterilization methods. Noxilizer sells sterilization equipment to pharmaceutical, biotech and medical device manufacturers and also offers contract sterilization services at its Baltimore, MD facilities. Noxilizer’s expert microbiology and material compatibility team is ready to partner to solve sterilization challenges through every phase of the process. To learn more about Noxilizer’s contract sterilization services or sterilization equipment please email info@noxilizer.com or visit www.noxilizer.com

Nuo Therapeutics, Inc. is a biomedical company that develops and commercializes individualized wound care therapies that harness a patient’s innate regenerative ability to stimulate wound healing. The Company’s flagship product, Aurix is a biodynamic hematogel derived from the patient’s own platelets and plasma, which is used at the point-of-care to jumpstart the natural healing process in a broad range of chronic wounds, including diabetic foot ulcers, venous leg ulcers and pressure injuries.

Based in Rockville, Maryland, OncoC4 is a privately-held, clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of novel biologicals for cancer treatment.

NantOmics is a molecular diagnostic firm that develops cloud-based molecular profiling tools that helps to guide cancer patients.

Mission We harness the power of molecular microbiology to develop diagnostic solutions that will optimize the treatment of life-threatening, drug resistant infections. We seek to dramatically transform patient care to guide antibiotic therapy selection and help improve antibiotic stewardship. About Headquartered in Rockville, Maryland, OpGen (NASDAQ:OPGN) is a precision medicine company harnessing the power of molecular diagnostics to help combat infectious disease. Our innovative approaches to infectious disease diagnostics consist of highly multiplexed syndromic molecular panels to address the global threat of antimicrobial resistance (AMR), improve antibiotic stewardship, and decrease the spread of multidrug-resistant microorganisms (MDROs). Together we improve patient care and fight AMR through cutting edge molecular microbiology.

Orgenesis is a global biotech company that has been committed to unlocking the potential of decentralized cell and gene therapies (CGTs) since 2012. Orgenesis established the POCare Network in 2020 to bring academia, hospitals, and Industry together to make these innovations more affordable and accessible to patients. In 2022, the POCare Services business unit responsible for developing and managing the decentralized POCare Centers and proprietary OMPULs was formed. Orgenesis will continue to focus on advancing to market through various partnerships its CGTs to provide a rapid, globally harmonized pathway for these therapies to reach and treat large numbers of patients at lowered costs through efficient, scalable, and decentralized production.

OriGene Technologies was founded as a research tool company focused on the creation of the largest commercial collection of full-length human cDNAs in a standard expression vector. The availability of the complete human genome sequence and the subsequent development of genome-based tools have enabled the identification of relevant drug targets through system biology approaches. OriGene's vision is to prepare comprehensive, genome-wide research tools and technology platforms to enable scientists to study complete biological pathways, thus enabling a better understanding of disease mechanisms including cancer and stem cell research. OriGene Technologies uses high-throughput, genome wide approach to develop products for pharmaceutical, biotechnology, and academic research. Our flagship product is the cDNA clone collection, a searchable gene bank of over 30,000 human full-length TrueClone cDNA collections and over 25,000 TrueORF cDNA clones. From our TrueORF cDNA clones, we have developed the largest offering of full-length human proteins expressed in mammalian cells, ideal for functional studies. In 2010, OriGene initiated the TrueMAB project to develop mouse monoclonal antibodies against protein antigens to develop protein assays for every human protein. In addition, OriGene offers unique gene expression products such as TissueScan cancer tissue qPCR arrays and tissue biorepository for biomarker discovery and validation OriGene is committed to its mission to be “Your Gene Company”, supplying everything a researcher needs for gene-based research. Visit us at https://www.origene.com

OspreyBio is a newly launched and first gene-and-cell-therapy-centric biotools company. Our core principle is to "Think Multigenic". From tools to make multi-effector AAVs to 8-gene (or more) constructs, Osprey is expanding its portfolio of products related to building multigenes, delivering large DNA, and reducing manufacturing costs to bring us all into the future of gene and cell therapy.

OS Therapies (OST) is a clinical stage therapeutic company focused on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors.

Otomagnetics is a medical device manufacturer that designs and commercializes magnetic injection system for the delivery of drugs to the inner ear.

OTraces has developed a blood-based disease testing platform that uses math- and physics-based noise suppression techniques never before employed in human disease testing, and has thereby achieved 90%+ accuracy in the detection of cancer tumors as measured by predictive power.

Our mission is to combat dysbiosis* in the human body. To that end, we aim to commercialize antimicrobial peptide therapies to safely restore balance to the gut's microbial flora and overcoming disease. P4 Microbiome was founded by Johns Hopkins University professors Phillip Phan and Jay Pasricha. The company took over the clinical development of P4M01 from the US Army in February of 2020. Together they recognized the immense potential of this discovery, not only for oral health, but also for solving dysbiosis in the GI tract. Beginning with our gingivitis indication, we will work our way down the gastrointestinal (GI) tract, addressing conditions including small intestinal bacterial overgrowth (SIBO) and irritable bowel syndrome (IBS) by correcting the underlying dysbiosis that drives pathology. *Dysbiosis: A change in the microbial composition, especially in the GI tract, that causes imbalance between beneficial and potentially pathogenic bacteria.

Catalent Inc. (NYSE: CTLT), an S&P 500® company, is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent supports our partners in introducing 200 new products and manufacturing over 70 billion doses each year. Since becoming a publicly traded company in 2014, we have grown to become a community of approximately 19,000+ workers who support over 7,000 products for over 1,000 customers around the world. We share a common goal: to put patients first and help people around the world live better and healthier lives. Catalyst + Talent. Our name combines these ideas. From drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your success. We have the deepest expertise, the broadest offerings, and the most innovative technologies to help you get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging results. more products. better treatments. reliably supplied.™ Your talents, ideas, and passion are essential to our mission: to develop, manufacture, and supply products that help people live better, healthier lives. Join us! Catalent hires people with a passion to make a difference to the health of millions of people globally. Your expertise, coupled with Catalent’s advanced technologies and collaboration with thousands of innovative pharmaceutical, biotech, and healthcare companies, will help bring life-enhancing products to life. Grow with us. Be challenged. Make a personal impact. Visit https://careers.catalent.com/us/en to explore career opportunities

microbial, bacterial, microbiology, clinical medicine, laboratory medicine, BACLIB

Personal Genome Diagnostics (PGDx) is empowering the fight against cancer by unlocking actionable information from the genome. We are committed to developing a portfolio of regulated tissue-based and liquid biopsy genomic products for laboratories worldwide.Our expertise in advanced cancer genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. We specialize in high-throughput next-generation sequencing, proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive approaches in cancer.

Pinion Immunotherapeutics is a Maryland based biotechnology company passionate about innovating safer and more efficient RNA preventive vaccines for infectious diseases and therapeutic vaccines for cancer.

The scope of experience of Polaris’s executive team spans nine decades & several fields, including military service, medicine, & federal research & development. These experiences have allowed the team to cultivate timely knowledge of pandemic-era mental health needs, & develop deeply unique qualifications to address these needs. The team has garnered numerous awards, ranks, titles, & accomplishments, ranging from captain to engineer, Purple Heart recipient to medical doctor, virologist & immunologist, 9/11 responder to Iraq War veteran, & PhD to Homeland Security Public Health Officer amid the threats of SARS & anthrax. In 2017, inspired by their work at the Defense & Veterans Brain Injury Center & the US Department of Veterans Affairs, a veteran & a scientist coalesced their visions seeded in service around the urgent need for 21st-century innovation in behavioral healthcare. Drawing upon decades of experience in biomedical technology, public health, & molecular biology, they founded a company to take aim at the mental health crisis that results in 22 veteran suicides each day. Partnering with the Illumina Accelerator & scientists from Mount Sinai & the Max Planck Institute of Psychiatry, the team developed the first-to-market, patented genomic biomarker assay to identify PTSD risk in 2018. As a veteran-owned business, our roots remain in our founding mission to improve the lives of US military service members & veterans living with behavioral health conditions, such as post-traumatic stress disorder (PTSD). In 2020, global public health events & an evolving behavioral health landscape revealed that the number of people standing to benefit from advances in diagnostics & treatment is broadening by the day. Guided by a calling to serve, we expanded our mission to encompass: - Veterans & active-duty US military service members, - First responders, frontline workers, & individuals in high-risk occupations, & - Trauma-exposed communities at large.

Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and commercialization.

Precision for Medicine is an industry-leading global clinical research services organization, purpose-built to improve the clinical research and development process for new therapeutics. Our novel approach integrates clinical operations excellence, with laboratory expertise, and advanced data sciences to inform every step. This maximizes our clients’ insight into patient biology, delivering more predictable trial outcomes and accelerating clinical development. We apply our expertise to trials at all stages—from early development through approval—with embedded experience in oncology and rare disease. With over 2000 dedicated professionals and 35 offices worldwide, we stand ready to help accelerate life-changing treatments anywhere around the globe.

Precision Molecular (PMI) is a clinical-stage company developing imaging biomarkers and theranostics for patients with cancer. They specialize in molecular imaging.

Previse is on a mission to save lives through the earlier detection and prevention of cancer, starting with esophageal cancer. They are actively working to get patients and healthcare providers the answers they need sooner by understanding and unlocking the power of biomarkers on cancer development and severity. Previse's technology was made possible by grants from the National Institutes of Health ("NIH") and developed after decades of research by the GI Early Detection Biomarker Lab at the Johns Hopkins University School of Medicine. An esophageal cancer diagnosis is something that nobody wants to hear. Today, this cancer takes 16,000 lives in the United States each year. The primary reason - the current detection method, upper endoscopy, is both invasive and expensive, so it's often not used until symptoms arise. In over 75% of cases, this is after the cancer has already spread and treatment options are limited, leading to esophageal cancer being the 3rd most lethal cancer in the United States (behind only pancreatic and lung cancer). Previse's early-detection system combines a simple routine test given as part of routine care with our patented DNA biomarkers that accurately test for disease. Our system is convenient, inexpensive, and accurate, so it can be given to those at risk before cancer symptoms, empowering patients to know earlier, receive necessary treatments, and live a healthier, longer life.

Primera Therapeutics is a company that provides patient-centric gene therapies targeting the causes of mitochondrial disorders. The company focuses on developing treatments for rare mitochondrial diseases for which there are no approved therapies. Primera Therapeutics is pioneering a first-in-class gene editing platform to cure genetic diseases.

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase II clinical trials for the treatment of necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase II clinical trials for the treatment of gastroparesis; and PCS6422, an oral, potent, selective, and irreversible inhibitor that is in Phase I clinical trials for treating metastatic colorectal and breast cancer. It has a license agreement with Akashi Therapeutics, Inc. to develop and commercialize PCS100, an anti-fibrotic and anti-inflammatory drug. The company was incorporated in 2011 and is based in Hanover, Maryland.

Propagenix is engaged in the development and commercialization of superior products to support a wide range of applications in basic and translational biomedical research. Our vision is to enable the creation of new and more effective drugs, personalized diagnostics and cell therapies that will enhance human healthcare. Using our powerful enabling technologies for culturing and differentiating epithelial stem cells, we are developing physiologically relevant in vitro tissue models that mimic biologic functions of both normal and diseased organs without the need for animal models. We are currently developing in vitro models for the important barrier epithelia of airway, kidney, and gastrointestinal tissues. Cells lining the airway can be damaged or destroyed by infection, disease, or injury. We are developing novel life science tools to support researchers engaged in • studying respiratory pathogens such as coronaviruses, influenza, respiratory syncytial viruses, adenoviruses, etc. • using epithelial tissue models for assessing drug and toxicant effects on airway, skin, and renal cell health, • use of clinically-relevant in vitro tumor models for solid cancers, and • developing cell therapy for diseases of the airway and epidermis where cell production is a bottleneck. Our business model is to support biopharma, CROs, and consumer product companies in their discovery and product development programs related to epithelial cell biology. We welcome inquiries from scientists who are interested in working with us to generate improved epithelial tissue models to support their research and development eforts. We also are open to inquiries on research collaborations from basic scientists leading to new product designs, as well as beta testers for our tissue models. Please to contact us at support@propagenix.com with your interest.

Protein BioSolutions provides viable solutions for scientists involved in DNA sequencing and in protein production, purification, characterization and crystallography.

Psomagen, Inc., formerly Macrogen Corp, delivers genomic sequencing services to the clinical, academic, and consumer markets. Psomagen's labs are US-based and CLIA and CAP certified. Not only is the company accredited to perform the highest quality Sanger sequencing, Next-Generation Sequencing and Microarray Gene Analysis, it is also networked with Macrogen's worldwide headquarters, stretching its capabilities and capacity across a diverse set of labs around the world. Learn more at psomagen.com.

Quality Biological (QBI) provides quality solutions for life science research and bioproduction applications. We specialize in producing custom and standard cell culture and molecular biology reagents, buffers, and liquid solutions and providing supporting services. At QBI, we help our clients achieve their application goals faster. We do this by being flexible and nimble, providing a level of personalized service our clients rely on. QBI is home to a fully-equipped, ISO 9001:2015 certified manufacturing facility. At the base of every product is water that exceeds industry specifications. This enables us to provide you with solutions of superior quality and value. We have your solution...whether you need a few liters of medium, buffer or a custom solution for research, dozens of liters of one single lot for process and method validation, or hundreds of liters for commercialization. We work with you to address your specific needs and requirements. Contact us today to discuss your specific media and buffer needs.

We work exclusively on orphan drugs and advanced therapies providing biotech partners with an integrated suite of strategic and operational regulatory services. Our regulatory team brings over 100 combined years of industry and consulting experience in orphan drug regulations and development. Made up entirely of Ph.D./MS-level/MD, senior regulatory strategists and mechanics, and all the passion in the world, they lead programs to success. Our Clients are those looking for strategic and operational support; someone who can be eyes-on and hands-on their program as and when needed; someone to help them navigate this complex regulatory pathway, and help them to decide when and how to submit their orphan applications, applications for accelerated approvals, and interactions with the Agencies. We plan, formulate questions, write, review, and/or submit. ­ - Regulatory operations ­ - Strategy & Development ­- Medical Writing ­- Publishing

Specializing in non-invasive prenatal genetic testing and paternity testing, Ravgen is focused on developing non-invasive prenatal diagnostic tests based on fetal DNA present in maternal blood. Diagnose single gene disorders, such as cystic fibrosis, sickle cell anemia and Downs syndrome, establish paternity and more early on in pregnancy.

RegeneRx is a publicly traded, clinical-stage, biopharmaceutical company focused on tissue protection, repair and regeneration. RegeneRx’s mission is to research and develop novel pharmaceuticals that protect and repair tissue and organ damage caused by disease, trauma or other pathology. RegeneRx’s management team is focused on moving three distinct Tβ4-based drug candidates through the clinic: RGN-137, RGN-259 and RGN-352. RegeneRx also holds over 75 issued patents or patent applications worldwide in order to enable and protect multiple indications and applications for its product candidates. Currently, RegeneRx has active partnerships in three major territories: the U.S. and Canada, China, and Pan Asia. Our partners have been moving forward and making significant progress in each territory with RGN-259, our ophthalmic drug candidate, and are preparing to initiate their clinical trials programs. In each case, the cost of development is being borne by our partners with no financial obligation for RegeneRx. Patient accrual, treatment, and follow-up for the ophthalmic trials are relatively fast, as opposed to most other clinical efforts, so data is typically forthcoming in months after patients begin enrollment. We have other significant clinical assets to develop, primarily RGN-352 (injectable formulation of Tβ4 for cardiac and CNS/PNS disorders) in the U.S., Pan Asia, and Europe, and RGN-259 in the EU. With respect to RGN-259, our goal is to wait until Phase 3 is completed in the U.S. before moving into the EU with RGN-259 in order to maximize value for the EU market. We intend to continue to develop RGN-352, either by obtaining grants to fund a Phase IIa clinical trial in the cardiovascular or central nervous system fields or finding a suitable partner with the resources and capabilities to develop it as we have with RGN-259.

REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees.

RenOVAte Biosciences Inc (RBI) is a Delaware Incorporated, Maryland based animal biotechnology company founded in December 2016. RBI is in the business of performing sophisticated and precision genome editing and genetic engineering in livestock species, to address critical priorities of animal and human health.

Restorative Therapies is a medical devices company that provides revolutionary Functional Electrical Stimulation devices and therapies to help patients achieve their full potential.

Rise Therapeutics is developing targeted immunological-based biologics using a unique and proprietary oral delivery platform. The company develops unique, first-in-class immune modulatory drugs for the treatment of inflammation, autoimmunity and cancer.

Founded in March, 2016, Rithim Biologics is a privately held, early stage startup company developing gene therapies to treat tachycardias (fast heart rates) in humans. Utilizing gene therapies, our initial efforts are targeting atrial fibrillation (AF) and more specifically those patients at risk for post-operative (cardiac) AF (POAF). POAF has been reported in 27% to 40% of coronary artery bypass graph (CABG) surgery patients.1 Worldwide, approximately 800,000 patients undergo CABG procedures annually.2 Postop AF has been reported in 14% to 60% of Valve Surgery patients.3 Worldwide, approximately 360,000 patients undergo heart valve surgery.4 Considering all patients with any type of AF, in the United States alone it is estimated to be a $26 billion burden on healthcare.5 1 Mathew JP, Fontes ML, Tudor IC, Ramsay J, Duke P, Mazer CD, Barash PG, Hsu PH, Mangano DT. A Multicenter Risk Index for Atrial Fibrillation. After Cardiac Surgery JAMA, April 14, 2004—Vol 291, No. 14 p. 1720 2 Filardo G , Damiano RJ Jr , Ailawadi G , Thourani VH , Pollock BD , Sass DM , Phan TK , Nguyen H , da Graca B. Epidemiology of new-onset atrial fibrillation following coronary artery bypass graft surgery. Heart. 2018 Jan 11. 3 Tanawuttiwat T, et al. New-Onset Atrial Fibrillation After Aortic Valve Replacement – Comparison of Transfemoral, Transapical, Transaortic, and Surgical Approaches. JACC, April 22, 2014 – Vol 63, No. 15 p.1510 4 Calculations based on Business Reports from Star Tribune, Medtronic Earnings , American Heart Association 5 Mozaffarian D, et al. Circulation 2016;133:e38-360.

At RNAimmune, we use mRNA technology to help people live full and healthy lives. Our primary focus is development of vaccines against cancer and respiratory viruses. Our expertise in design and production of mRNA vaccines is supported by research and development efforts toward novel lipids, targeted delivery and antigen engineering. We collaborate with the world for the health of everyone.

Tracking System for MRI Guided Interventions

RoosterBio accelerates human mesenchymal stem/stromal cell (hMSC) and exosome/extracellular vesicle (EV) product and process development to fuel the rapid implementation of scalable advanced therapies. Our high-quality hMSCs, bioprocess media, genetic engineering tools, and exosome production solutions are paired with expert bioprocessing knowledge to progress therapeutic developers from concept to first-in-human testing and commercial manufacturing at reduced cost and increased productivity. With optimized, scalable processes, Type II Drug Master Files, and cGMP products, we have enabled therapeutic programs to traverse their path to clinical translation in under one year. RoosterBio is driven by our client's success and creating a world where safe and effective advanced therapies are rapidly developed and widely available on a global scale.

RS BioTherapeutics is a research, development, and commercialization company focused on developing life-changing medicines for pulmonary diseases. The company's mission is to harness the therapeutic power of cannabinoids in the research, development, and commercialization of these medicines.

SalubrisBio was founded in August 2016 as a subsidiary of the China-based pharmaceutical company Salubris Pharmaceuticals Co. Ltd. (www.salubris.com). SalubrisBio is an innovation-focused biotech with pioneering research and development programs. Headquartered in Gaithersburg, Maryland, SalubrisBio represents and reflects Salubris Pharmaceuticals’ commitment to innovation and expansion into the global market. SalubrisBio focuses exclusively on the discovery and global development of novel, biologic therapeutics. Salubris Pharmaceuticals is a publicly-traded company [002294:CH], founded in 1998, which has grown to achieve sales of >$750M USD in 2016. Salubris Pharmaceuticals is a fully-integrated drug development company. Headquartered in Shenzhen, China, Salubris Pharmaceuticals has over 3,000 employees working across R&D, regulatory, marketing and sales. Its marketed products include small molecule drugs in the cardiovascular, anti-allergy and anti-infective therapeutic areas. GeneKey Biotech Ltd. Co. (www.genekeybio.com), based in Chengdu, China, is the China-based biologics subsidiary of Salubris Pharmaceuticals. GeneKey Biotech has a robust portfolio of biosimilar and novel large molecule therapeutics in development in China. SalubrisBio maintains close cross-functional collaborations with GeneKey Biotech, leveraging resources including the expertise of >150 research scientists and large-scale manufacturing of up to 2000L scale.

Sanaria is a biotechnology company dedicated to the production of a vaccine protective against malaria caused by the pathogen Plasmodium falciparum. Sanaria’s vaccine is based on an approach to immunization that has already proven highly protective in humans.

Sapio Sciences' mission is to improve lives by accelerating discovery, and because science is complex, Sapio makes technology simple. Sapio is a global business offering an all-in-one science-aware (TM) lab informatics platform combining cloud-based LIMS, ELN, and Jarvis data solutions. Sapio serves some of the largest global and specialist brands, including biopharma, CRO/CDMOs and clinical diagnostic labs across NGS genomic sequencing, bioanalysis, bioprocessing, stability, clinical, histopathology, drug research, and in vivo studies. Customers love Sapio's platform because it is robust, scalable, and with no-code configuration, can quickly adapt to meet unique needs.

Extended release formulation technology

Scanogen is a molecular diagnostic company developing systems to read the biomolecular information of body fluids with the goal of improving health care. The Company has developed Single MOLecule Tethering (SMOLT), a proprietary technology for rapid and ultra-sensitive detection of biomolecules. The Company is using this technology to develop a simple-to-use and sample-to-answer diagnostic platform. Scanogen has received NIH grants totaling $9.5 million to develop its diagnostic assays and it is currently focused on two areas: Point-of-care diagnosis and bloodstream infection detection.

Revolutionizing cell therapy to address inflammatory diseases driven via neonatal cardiac progenitor cells and their secretomes.

Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company, engages in the discovery and development of therapies with an initial focus on treatments for cancer. The company develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response. It is engineering ImmunoPhage product candidates to directly target antigen presenting cells and modulate the tumor microenvironment through the targeted use of nanobodies which further enhances therapeutic activity. Sensei Biotherapeutics, Inc. was formerly known as Panacea Pharmaceuticals, Inc. The company was founded in 1999 and is headquartered in Rockville, Maryland.

Senseonics, Inc. is a medical device startup company in Germantown, Maryland, USA (near Washington, DC) developing transformative glucose monitoring products that are intended to enable people with diabetes to confidently live their lives with ease. Utilizing breakthrough fluorescence sensing technology, the Senseonics continuous glucose monitoring ("CGM"​) system is being designed to be the first fully implantable CGM that is highly accurate and stable throughout its long sensor life. The system consists of a very small sensor implanted under the skin, an external transmitter, and a mobile medical application, which allows for discreet, easy access to real-time glucose measurements without the need for a dedicated receiver.

SeraCare, part of LGC's Clinical Diagnostics Division, enables the promise of precision medicine by advancing the understanding of disease and providing assurance of the diagnostic result. Our innovative tools and technologies not only ensure the safe, effective, and accurate performance of diagnostic assays but also establish a framework for regulating, compiling, and interpreting data from precision diagnostics. Our portfolio includes a broad range of products such as quality control technologies, disease-state specimens and tissues for research and development, processed biological materials, and immunoassay reagents.

Seraxis is a privately owned biotechnology company. Our GMP lab is located in Germantown, Maryland, in the heart of the vibrant BioHealth Capital Region. Launched in early 2013, Seraxis used proprietary technologies to develop a cell replacement therapy, SR-01, that is more effective and safer than embryonic stem cell-derived therapies. Our highly pure insulin-producing cells are micro-encapsulated through a proprietary technology that enables the function of human pancreas cells in type-1 diabetes models without the need for immuno-suppression. Seraxis intends to bring SR-01 to the clinic in order to provide a cure for the devastating disease of diabetes.

SereNeuro Therapeutics is developing breakthrough non-opioid advanced therapy treatments for pain at scale.

Shuttle Pharmaceuticals is a clinical-stage pharmaceutical company developing novel therapies and diagnostics to improve the outcomes for cancer patients treated with radiation therapy. Our technology sensitizes growing cancer cells, rendering them susceptible to the effects of radiation therapy, activates DNA damage and innate immune responses and offers the potential to integrate with checkpoint inhibitors and immune therapies. Our mass spectrometry-based diagnostics platform is focused on predicting clinical outcomes to inform clinical decisions for patients electing to receive radiation therapy for prostate cancer.

Sigmovir Biosystems is a biotechnology company that specializes in the cotton rat model of human infectious diseases.

Sonavex, Inc. is a Baltimore-based medical device company originally spun out of Johns Hopkins focused on Empowered Patient Care. The company has developed a portfolio of novel ultrasound solutions that empower patient care by delivering critical visual and quantitative data to improve outcomes and reduce costs. EchoMark is a bioresorbable and highly echogenic (visible under ultrasound) implant used to mark at-risk blood vessels such that the site can be easily assessed for future complications. EchoSure is a deep-learning enabled 3D automated ultrasound device designed to be used by healthcare providers without ultrasound training to assess blood flow and morphology of vessels marked by the implanted EchoMark device. For more information, please visit http://www.sonavex.com

Sonogen Medical is a medical devices company developing next generation ultrasonic bone fracture healing technology, based on highly innovative applications of low-intensity pulsed ultrasound (LIPUS).

Sotelix Endoscopy is a privately held medical device startup focused on developing groundbreaking therapeutic endoscopy devices for minimally invasive treatments in the gastrointestinal tract. Sotelix Endoscopy is based in Baltimore, MD.

Speed BioSystems is a biomedical research reagents company that offers high-quality products with speedy delivery services.

We are a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Our extensive expertise in product development has been built over the past 25 years: initially as a standalone development organization, then as a U.S. subsidiary of Shire plc and, in late 2005, as Supernus Pharmaceuticals Inc. We market our products in the United States through our own specialty sales force and seek strategic collaborations with other pharmaceutical companies to license our products outside the United States. We market Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy, Apokyn® (apomorphine hydrochloride injection) for the acute treatment of hypomobility in advanced Parkinson’s disease (PD), Myobloc® (rimabotulinumtoxinB) for the treatment of cervical dystonia and treatment of chronic sialorrhea in adults, and Xadago® (safinamide) as an adjunctive treatment to levodopa/carbidopa in PD patients with hypomobility. We are also developing several product candidates to address large market opportunities in the CNS market, including SPN-812 for the treatment of ADHD, apomorphine infusion pump for hypomobility in PD, SPN-820 (NV-5138) for treatment-resistant depression, and SPN-817 for the treatment of epilepsy.

Sysmex Inostics is a medical diagnostics company that specializes in cancer testing through liquid biopsy technology, catering to precision medicine.

TEAMEDON INTERNATIONAL, LLC is a company based out of 10134 TREBLE CT, ROCKVILLE, Maryland, United States.

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company focused on developing Telomir-1 as the first novel small molecule to lengthen telomeres, which are protective structures at the ends of chromosomes that play a key role in cellular aging and disease. The company is dedicated to the development and commercialization of therapeutic products for the treatment of age-related diseases and conditions.

Texcell is a dedicated partner for biotechnology and pharmaceutical companies since more than 2 decades. Thanks to an unique combination of expertise in Virology and Immunology, we can provide a full support to your product development from the proof of concept to clinical studies and GMP manufacturing. Our state-of the Art facilities are located in France, Germany and in the US where we use most recent technologies to efficiently perform a wide range of assays What do we provide ? A specialized analytical lab for your preclinical and clinical studies, including: - Cell based assays/potency assays during development - Immunogenicity, TK/PK, ADA and neutralizing Antibody Testing - Immunotoxicology studies - Sample pre analytics: serum/plasma isolation, PBMC isolation & storage - Biobanking - Read-outs: ELISA, ECLIA, Flow cytometry, ELISpot, HAI, proliferation... Texcell Viral Safety lab: Expertise in biosafety of biological and pharmaceutical products. - Virus/TSE Validation - Viral Clearance study - 25 model viruses available - spiking in L2 and L3 labs... - Viral safety testing - a complete range of tests (NGS, in vitro, in vivo, TEM, Q-PCR…) to characterize cell banks and ensure microbiological safety (viruses, mycoplasma, etc…). - Cell and Gene therapy (ATMPs) and Biodistribution/biodissemination - experience with adenovirus, retrovirus, lentivirus... - Virucidal Norm and cleaning validation - Standard Toxicology and Medical Device Biocompatibility studies (ISO 10993) Texcell GMP cell bank facility: Expertise in handling and growing more than one hundred mammalian cell lines. - Production of RCB, MCB and WCB in GMP - Modern class B and class C cell culture room - Dedicated class B room to fill automatically cells in vials - Culture of adherent and suspension cell line with single use disposable - Viral safety control of cell banks performed directly in-house For more information visit www.texcell.com.

Developed a computational platform that converts recombinant proteins intomaterial-binding variants that can be used to coat implants, devices, and injectable carriers.

TEDCO enhances economic empowerment growth through the fostering of an inclusive entrepreneurial innovation ecosystem. TEDCO identifies, invests in, and helps grow technology companies in Maryland. Take our customer satisfaction survey and let us know how we're doing: https://tedco.tfaforms.net/40

Theriva Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need. The Company advanced into oncology through the acquisition of VCN Biosciences, S.L. (VCN), who have developed a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient's immune system. The Company's lead candidates are: (1) VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment; (2) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR), and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (3) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.

Eight and a half million Americans live with non-healing wounds. Caring for these conditions unfortunately relies heavily on guesswork and approximations, perpetuating expensive and ineffective treatments. Care providers simply do not have the tools necessary to accurately track wound healing over time. Tissue Analytics is bringing wound care into the 21st century by turning the common smartphone into a sophisticated imaging platform. Tissue Analytics has developed proprietary image analysis algorithms that completely standardize wound documentation, allowing clinicians to make more informed decisions and heal patients faster.

Kolon TissueGene is a biotechnology company that specializes in developing cell and gene therapy for osteoarthritis diseases.

TrimGen is a precision medicine company that specializes in pharmacogenomics for behavioral health and chronic pain.

Trophogen, Inc. is a biotechnology company founded in 2001 with series A funding from Toucan Capital, focusing on the development of high affinity glycoprotein hormone and related growth factor analogs for human and animal infertility as well as targeted therapy and imaging of thyroid, ovarian, breast, prostate and testicular cancers.

Uniformed Services University is a medical education institution that specializes in training healthcare professionals for military service.

Since its inception in 1969, USAMRIID has spearheaded research to develop medical solutions, vaccines, drugs, diagnostics, and information to protect military service members from biological threats. Its specialized capabilities include Biosafety Level 3 and Level 4 laboratories, world-class expertise in the generation of biological aerosols for testing candidate vaccines and therapeutics, and fully accredited animal research facilities.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. We currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! Our employees can be found collaborating across the United States, Europe and Asia. As a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases.

US Biolab is a global commercial biobank and human biospecimen CRO providing solutions to biopharmaceutical and academic researchers. We are specializing in contract services for human sample validation studies such as sample collections & histology services. Our expertise is precision medicine and biomedical research projects including biomarker R&D and translational medicine. Our Biobank/repository preserving more than 300,000 high-quality bio-samples, we has developed more than 300 types of tissue microarray and cell microarray products. Sample selection from our bank and customization are both available to build the most satisfactory tissue microarrays. Partnering with us allows you to greatly accelerate and improve your research with guaranteed quality.

VaLogic is a reliable and trusted partner for GxP compliance. We offer a wide range of services, including calibration, CQV (Commissioning, Qualification, and Validation), environmental monitoring, and certification. Our specialization in pharmaceuticals, biotechnology, and life sciences ensures that we guarantee unwavering compliance, operational efficiency, and excellence. Choose VaLogic as your preferred GxP compliance service provider today! Specific scope of offerings include; DESIGN — Facilities and Clean Rooms — Critical Utilities — Controlled Temperature/Humidity Rooms — Quality Systems appropriate to phase of GMP — Risk-based Validation BUILDING / IMPLEMENTING — Integrated Commissioning & Qualification — Equipment Management & Monitoring — Asset Management System (LogiCalTM) — Facility Monitoring System (LogiPointTM) — Contamination Controls — Risk-based Quality System — Walk-in Cold Rooms, Freezers, and Clean Rooms — Calibration & Validation Programs — CMC Regulatory Submissions MAINTAINING — Biorepository Service — Environmental Monitoring — Laboratory Support Services (EM/Water/Steam/Gas) — Inspection Readiness — Risk Management — Troubleshooting & Application of Industry Best Practices

Valted Seq is a discovery stage biopharmaceutical company spearheaded by world-renowned scientists Dr. Ted Dawson and Dr. Valina Dawson of Johns Hopkins University. The company was founded on the belief that a deeper understanding of neurodegenerative pathways is essential to develop precision therapeutics and identify novel biomarkers for some of the most challenging neurodegenerative diseases, including Alzheimer’s and Parkinson’s. Valted Seq is part of the D&D Pharmatech/Neuraly family of companies, which works hand in hand with leading medical research institutions to advance groundbreaking healthcare innovations. ValtedSeq is focused on the advancement of NextGen sequencing at the single cell level, as well as developing assays for diagnostic biomarkers,

VERACHEM LLC is a biotechnology company based out of P.O. BOX 2206, GERMANTOWN, Maryland, United States.

The company operates a GMP biorepository and performs bioservices such as cell banking, tissue banking, and clinical sample management.

Vita Therapeutics - We are a team of dedicated scientists striving to advance treatments in multiple indications in our cell therapy platform. Our mission is to utilize the power of genetics to deliver life-transformative cell therapies by unlocking the potential of engineered cellular medicine.

VLP Therapeutics, Inc. (VLPT) was established in 2013 by seasoned biopharmaceutical veterans with mission to develop innovative medical treatment which transforms traditional vaccine and targeted antibody therapies to address global unmet medical needs. Its vision is to combat the 21st century global public health problems through revolutionary next generation i-αVLP (inserted alpha VLP) Technology. The company is headquartered in Gaithersburg, Maryland.

Westat offers innovative professional services to help clients improve outcomes in health, education, social policy, and transportation. We are dedicated to improving lives through research. Expertise • Data Collection & Management • Clinical Trials • Statistical Research & Survey Methods • Evaluation • Communications & Social Marketing Staff and Locations Westat’s staff of more than 2,000 are located at our headquarters in Rockville, Maryland, near Washington, DC. Additional staff are located at Westat’s data collection survey processing facilities, at our Telephone Research Center facilities, and throughout our nationwide field operations. Westat also maintains research offices near our clients in Atlanta, Georgia; Cambridge, Massachusetts; Raleigh/Durham, North Carolina; Philadelphia, Pennsylvania; Houston, Texas; and San Antonio, Texas. We have international offices in Liberia, Costa Rica; Johannesburg, South Africa; and Bangkok, Thailand. Westat is committed to providing accessible media on LinkedIn. Should you experience difficulties with any posted media, please send us a message at Section508Coordinator@westat.com. An alternative format will be provided upon request.

Xcision Medical Systems, LLC is a medical technology company that has developed the GammaPod, an advanced stereotactic radiotherapy system with the potential to significantly improve the convenience and quality of life for patients with early-stage breast cancer. The company's technology is designed to extend the benefits of radiation oncology to more patients and enable precision noninvasive treatments that allow patients to return to living fuller lives more quickly with less discomfort after receiving a cancer diagnosis. The system has been developed based on a patent licensed from the University of Maryland School of Medicine.

xMD Diagnostics, Inc. is a molecular diagnostics tools company focused on developing a line of laboratory instruments and consumables for the rapidly growing research, biopharmaceutical and commercial clinical laboratory (CLIA) precision diagnostics markets. xMD's goal is to significantly improve pathologists', oncologists' and other physicians' ability to diagnose, monitor and treat patients with cancer and other serious genetic diseases.

Located in Frederick, MD, XpressBio is a small biotechnology company that manufactures and markets molecular and immunological products and services to the bioscience research community worldwide. Because XpressBio scientific officers are comprised of an elite group of pioneers in immunology and molecular biology, our customers are some of the world's leading pharmaceutical, biotechnology, government, and academic organizations. We are committed to satisfying our customers' expectations by providing high-quality products and services matched by superb customer service. Our research capabilities and extensive experience allow XpressBio to continuously expand its product portfolio by responding to the needs of clients for a personalized solution. Partnering with clients in this manner allows us to customize products for client needs while simultaneously expanding our product offering. Together, we can conquer manufacturing and product development challenges in a rapidly evolving environment.

Zyngenia is a biotechnology company that develops highly specific, single molecule biotherapeutics targeting multiple physiologic pathways to treat complex diseases like cancer and inflammation.